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Summary 
Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and 
induced pluripotent stem cells (iPSCs) have the capacity to self-renew while maintaining the 
ability to differentiate into cell types derived from all three germ layers (endoderm, mesoderm, 
ectoderm). They have a high potential as a cell source in the field of regenerative medicine, drug 
development, disease modelling and early embryonic development. Multiple criteria have been 
proposed to evaluate hPSCs such as morphology, karyotype, cell surface phenotype, gene 
expression profile, in vitro differentiation as well as in vivo differentiation. However, there are 
many inconsistencies in the way of generating and reporting the results, most particularly 
concerning the formation of teratoma in vivo, which is the gold standard for the demonstration of 
pluripotency. The place of implantation, the number of injected cells as well as the duration of 
the assay introduce high level of variability with various consequences, including absence of 
detectable teratoma formation.  
In the first part of the thesis I report the generation of four hESC lines under the same conditions. 
They were characterized for their pluripotency status, their gene expression profile and their 
differentiation behaviour in vitro. We showed that although derived and cultured in identical 
conditions, the 4 hESC lines exhibit differences in their gene expression pattern and their 
propensity to spontaneously commit during their maintenance. We also demonstrated that these 
differences have further consequence for their directed differentiation into neuronal tissue.  
In the second part of the thesis I present the establishment of a new perfusion-based 3D in vitro 
culture system, which allows the formation of teratoma-like structures derived from all three 
germ layers. We show that the perfused culture allows spontaneous differentiation of hPSCs into 
the three embryonic lineages in a more efficient, balanced and reliable way than previously used 
in vitro systems. This leads to the formation of teratoma-like tissue structures similar to those 
observed in vivo. Finally, we defined a quantitative system to grade teratomas, which indicates 
that our in vitro culture is as efficient but more controlled and reproducible than the in vivo assay. 
That grading method could also potentially be used to compare hPSC lines properties in our 
system. 
Taken all results together, my thesis illustrates the complexity of hPSCs and the extensive need 
of standardized processes to derive, to maintain and characterize their pluripotency status.  
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General Introduction 
A. Stem cells 
1. Overview 
Stem cells are biological cells found in almost every multicellular organism. They are the source 
of every cell types during development. In adults, they allow normal regeneration of tissues (like 
skin or blood) but are also required to repair damaged tissues. They are able to self-renew, but as 
well to differentiate into various cell types. During periods of growth and regeneration, stem cells 
are able to divide symmetrically to generate two identical copies thereby expanding stochastically 
their cell numbers (1). One way to accomplish both self-renewal and differentiation is the 
asymmetric cell division whereby each stem cell divides to one daughter cell, that maintains stem 
cell identity and to one that further differentiates into another type of cell with a more specialized 
function (2). This capacity is crucial to maintain the number of stem cells, while still allowing the 
production of new more differentiated cells (1). 
2. Different types of stem cells have different biological functions and differentiation 
potency 
Stem cells are present both in embryonic and adult organisms. However, the so called embryonic 
stem cells (ESCs) and somatic, or adult, stem cells exert different biological role and therefore 
exhibit different potency to differentiate into other types of cells. Stem cells are thus often 
categorized based on their differentiation potency (Figure 1) (3).  
2.1 Embryonic stem cells (ESCs) 
ESCs are formed in pre-implanted embryos, after division of the zygote until the blastocyst stage 
(Figure 1). At early stages, from the fertilized egg up to the 4-cell stage embryo, the blastomeres 
have the greatest differentiation potential and are considered to be totipotent. These cells are 
capable of developing into a complete organism as they can give rise to every type of cell of the 
embryonic body as well as to extra-embryonic cell types (chorion, placenta) (4). At the 16-cell 
stage (morula), the cells start to differentiate and to develop in an inner cell mass (ICM) or into 
cells of the outer trophoblast. During this development, the cells belonging to the ICM lose their 
totipotency and become pluripotent. They are still able to give rise to every cell types that derive 
from all three embryonic germ layers (endoderm, mesoderm and ectoderm) but are no more 
capable to give rise to extra-embryonic tissues. Those two types of stem cells are the only one 
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that can give rise to zygotes, through generation of germ cells, which are reprogrammed during 
fertilization to generate new totipotent stem cells. Because of their unlimited division capacity, 
they are virtually immortal (5, 6). 
 
 
Figure 1: Stem cell hierarchy. The zygote until the morula stage is defined as totipotent, since a whole organism can 
be built. The cells of the ICM of the blastocyst are able to differentiate into the three germ layers and to the 
primordial germ cells. In adult tissue, multipotent stem cells are able to give rise to cells within the germ layer but 
also to cells of other lineages. Progenitor cells are restricted to differentiate into cells within one tissue (adapted from 
(3)) 
2.2 Somatic stem cells  
Somatic stem cells are found in a variety of tissues in the body. They are more specialized cells 
and thus more restricted in their differentiation potential. They originate in one germ layer and 
can usually only form different derivates of the same germ layer (like mesenchymal stem cells 
and endothelial stem cells). They are at best multipotent (lineage restricted) and are committed to 
give rise to several distinct but closely related cell types (e.g. fat-to-muscle within the 
mesodermal lineage). They can also be oligopotent (like bone marrow stem cells) and then able 
to differentiate into a few different cell types within one tissue. Somatic stem cells can even be 
unipotent only being able to produce one cell type but still self-renewing which distinguish them 
from progenitor cells. None of those cells are immortal but they exhibit high level of division (7, 
8). 
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3.  Biological and experimental recovery of stemness 
3.1. De-differentiation and transdifferentiation 
While pre-existing stem cells are used during the natural process of tissue renewal, newly 
generated stem cells through de-differentiation of somatic cells can also be involved, particularly 
in the case of tissue regeneration after injury (Figure 2). Thereby a fully differentiated cell 
retrieves back to a less-differentiated stage within its own lineage. This way, the cells proliferate 
before they re-differentiate and subsequent replace those cells that have been lost. In some cases, 
de-differentiated cells may re-differentiate into a different cell type of the same lineage (e.g. fat-
to-muscle within the mesodermal lineage) but can also transdifferentiate to cells of other germ 
layers (e.g. bone marrow-to-neurons between mesodermal and ectodermal lineages) (9, 10). Two 
models actually exist to describe the process of transdifferentiation. As explain above, one 
proposes that the cell must first dedifferentiate to a precursor or a stem cell stage before it can 
start to differentiate into a cell type of another lineage. The other proposes that transdifferentation 
can occur without going via the intermediate precursor step. However, this phenomenon was not 
observed during a natural process, but rather happens during experimental induction of 
transdifferentiation (10, 11). 
3.2. Recovery of pluripotency 
While somatic cells may sometime give rise to adult stem cells through de-differentiation, they 
do not seem to be able to naturally de-differentiate back to a pluripotent state. The only process 
where cells are fully reprogrammed naturally is during fertilization, in which totipotent stem cells 
are produced to differentiate into any type of cells in the body. Nevertheless, somatic cells can to 
be reprogrammed artificially by introducing specific transcription factors to reach the pluripotent 
state again (reviewed in (11, 13)) 
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Figure 2: Different model of differentiation. (a) During development and regeneration stem cell or progenitor 
cells differentiate to a specific cell type. (b) In case of injury, differentiated cells may de-differentiate to an 
early fate to become a progenitor or a stem cell again. (c) In some cases, differentiated cells may differentiate 
into another mature cell type (also of another lineage), which is called transdifferentiation. It can occur either 
directly or through the de-differentiation step before they re-differentiate to the new mature cell type (adapted 
from (12)). 
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B. Derivation and maintenance of natural and induced pluripotent stem cells 
As already mentioned the essence of human pluripotent stem cells (hPSCs), including human 
embryonic stem cells (hESCs) and experimentally induced pluripotent stem cells (iPSCs) is the 
ability both to intrinsically self-renew and to differentiate into other cell type that derive from all 
three germ layers, such as muscle, intestine, neurons or skin cells (5, 6). Due to their 
characteristics, they are promising in different fields of research and medicine and a lot of effort 
by many laboratories during the last decades has now allowed the isolation, maintenance and 
amplification of many hPSC lines in culture (14). 
1. hESCs  
1.1 A brief historic overview 
The derivation of the first human embryonic stem cell line was reported in 1998 based on the 
derivation of mouse embryonic stem cells (mESCs) in 1981 (5, 15, 16). The development of 
ESCs evolved out of the pioneering work on mouse teratocarcinoma, which is the malignant form 
of the teratoma, comprised of several undifferentiated tissues besides the differentiated tissues 
(17). They isolated PSCs (embryonic carcinoma cells or ECCs) out of the teratocarcinoma and 
demonstrated that they could differentiate into various different cell types. The expanded research 
on ECCs also demonstrated that it was possible to generate chimera by injecting ECCs to a 
murine blastocyst. Furthermore, those ECC were used as an in vitro model for early mammalian 
ESCs and to investigate different processes occurring during mammalian development (17).  
Nevertheless, these cells had several limitations, they had often chromosomal abnormalities and 
the capacity to differentiate into different cell types remained limited. Since it was possible to 
induce a teratocarcinoma by injecting a blastocyst ectopically, Martin and Evans realized 
independently from each other that it might be possible to derive pluripotent stem cells directly 
from blastocysts. These findings led then finally to the derivation of mPSCs directly from the 
mouse blastocyst (15, 16). Next, primate ESCs from rhesus monkeys and later on from marmoset 
were isolated in 1995 (18, 19). In 1998, the same laboratory was able to derive hESCs out of 
excessed blastocysts, which were donated by infertile couples undergoing assisted reproduction. 
The technique to isolate hESCs was not very different from the one to generate mESCs. They 
isolated the ICM of single blastocysts and plated the cells on mouse embryonic fibroblasts. 
During establishment, they realized that the properties of the hESCs are different from those of 
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mESCs and that they require different culture conditions. By contrast, the primate ESCs resemble 
much more hESCs in terms of morphology, genes expression and lack of response to the growth 
factor LIF (20). 
1.2 Derivation of hESCs 
The establishment rate of generating a hESC line from a donated embryo is around 3–10% and is 
highly dependent on the technique and the developmental quality of the embryo (21). Most 
hESCs are derived from human embryos that have been originated during assisted reproduction 
and being in excess for clinical needs. In some countries, the law allows the generation of 
embryos specifically for research purposes (such as UK and Belgium) but for ethical reasons 
most of the generated hESC lines are derived anyway from surplus embryos (22). Swiss law 
allows the generation of hESC lines from surplus embryos donated for stem cell research 
exclusively (Stammzellenforschungsgesetz (StFG), in vigour since 2003). However, most of the 
established hESC lines, including those obtained in our laboratory (23) were derived from 
blastocyst-stage embryos (5-7 days after fertilization) by isolating the ICM. Some hESC lines 
have been generated from earlier-staged embryos or even from single blastomers (24, 25). This 
procedure has been performed to avoid the destruction of human embryos that are in a later stage 
of development but the likelihood for producing a hESC line is lower (22).  
1.3. Maintenance of hESCs 
When the first hESC lines were established, very similar culture medium and conditions as those 
for the culture of mESCs were used. However, since novel involved signaling pathways was 
detected, new reagents to maintain hESCs culture were developed and the culture conditions 
evolved considerably since then (26). 
Several components required for the growth and the maintenance were identified, such as (i) 
basic medium, (ii) protein source, (iii) factors used to stimulate pluripotency (e.g. FGF-2), (iiii) 
cell support (e.g. feeders, matrigel). A huge variety of different compounds exist to maintain the 
culture conditions of hPSC in vitro (22). 
The most commonly used basic culture medium and protein source to culture hPSCs is the 
knockout-DMEM (KO-DMEM) supplemented with knockout-serum replacement (KSR). The 
medium has a reduced osmolality, which favors growth of hPSCs. KSR, a mixture of required 
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factors, replaces regular fetal serum (FBS) and thus enables growth and differentiation while 
avoiding the presence of multiple undefined components (22). 
The hESCs were originally cultured on mitotically inactivated mouse embryonic fibroblasts as 
feeder cells. To avoid the number of xeno-components, they were progressively replaced by 
mitotically inactivated human fetal fibroblasts. Through the secretion of essential growth factors, 
feeders support the self-renewal of hESCs. New culture conditions have been established where 
hESC could be cultured on a feeder-free basis requiring a matrigel or laminin layer (27, 28). 
Furthermore, hPSC culture requires extrinsic growth factors to support pluripotency.  The 
leukemia inhibitory factor (LIF) supports the undifferentiated state for mESCs. In some 
conditions, it is also used in hESC culture. However, the most commonly used growth factor for 
hESC culture is FGF-2 (or ßFGF). It promotes self-renewal in two different ways: it directly 
activates the mitogen-activated protein kinase (MAPK) pathway in the cell, and indirectly it has 
an influence on the feeder cells to modify TGFβ1 and activin A signalling pathway. These three 
pathways play a central role in the maintenance of pluripotency and self-renewal (29). 
hESC have a poor survival rate after their dissociation of the cells into single cells, which is 
regularly done for passaging other cell types. hESCs are more sensitive to treatments and are 
vulnerable to cell death. Thus, the cells need to be passaged as aggregates either mechanically 
using a scalpel or by enzymatic dissociation. However, in some cases single cell dissociation 
needs to be performed (e.g. for embryoid body formation). The latter requires Rho-associated 
protein kinase (ROCK) inhibitor (RI) to maintain cell survival by preventing dissociation-induced 
apoptosis (30). 
1.4 The pluripotency state in human as compared to mouse ESCs 
Despite similar origins there are several differences between hESCs and mESCs: (i) the colony 
morphology, whereby the hESC have a flattened appearance as compared to the mESC being 
“dome” shaped (ii) some pluripotency markers differ, e.g. hESCs express SSEA-3 and SSEA-4 
instead of SSEA-1 as in mESCs, (iii) hESCs are sensitive to single cell dissociation and therefore 
need to be passaged as cell aggregates, in contrast to the mESC, (iiii) different signaling 
pathways are involved in the maintenance of pluripotency. mESCs depend on the LIF/BMP4 
pathway whereas hESC use the FGF/TGFß signaling pathway. These differences were always 
associated to the fact that different developmental programs exist between human and mice. 
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However, this assumption was questioned when it was discovered that different types of PSCs 
can be isolated from mice (31) (Figure 3). 
 
 
Figure 3: The pluripotent lineage in the mouse embryo. Until the embryonic day (E) 2.5, cells are totipotent. At 
E3.5 the ICM of the blastocyst contains cells expressing pluripotency and extra-embryonic endoderm. At E4.5 
the epiblast and the primitive endoderm lineages segregate. At this stage mESCs are retrieved from the epiblast 
and are called naïve. Shortly after this step, the embryo implants in the womb. The embryo further develops 
and the EpiSCs derive which are in a primed pluripotent state (adapted from (32)). 
 
ESCs are isolated from the ICM of the pre-implanted mouse or human blastocysts. Epiblast stem 
cells (EpiSCs) are isolated from mouse post-implantation embryonic epiblast stage embryos 
(Figure 3). Due to ethical aspects, the derivation of EpiSCs in human was not attempted. ESCs 
are often termed as “naïve” pluripotent stem cells. They are unprepared to make lineage decisions 
and have to pass a maturation process. In contrast, the EpiSCs are defined as “primed” 
pluripotent stem cells. They are partially specified and prone to a specific cell fate. The EpiSCs 
express the main pluripotency markers (Oct4, Sox2 and Nanog), are able to differentiate in vitro 
and can build a teratoma. However, the mouse naïve and primed ESCs differ in the way that 
naïve ESCs are able to form chimeras upon blastocyst injection whereas primed ESCs are 
incapable. It has been proposed that the EpiSCs correspond to a more advanced developmental 
stage. Furthermore, they differ from the ESCs in the expression of several different transcription 
factors (33, 34). The hESCs show an expression pattern more similar to mouse EpiSCs than to 
the mouse ESCs and may represent a later step of differentiation than the mouse ESCs. However, 
their naïve or primed nature cannot be evaluated since human chimeras cannot be built due for 
obvious ethical reasons (32, 35). Different attempts were done to generate human naïve cells, 
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which relied on transgene expression using specific inhibitors to target different signaling 
pathways (31). 
1.5 Variation of the hESCs 
Although all hESC lines share the same properties, differences between lines often exist in terms 
of genetic stability during long-term culture and differentiation potential into specific cell types 
(36, 37). The mentioned variability in generating and maintaining hESCs makes the interpretation 
and conclusions of inter-line differences difficult. No conclusion can be drawn if the difference is 
due to inherent genetic variation or due to environmental influences like the culture conditions. 
Furthermore, it has to be considered that the maintenance of the pluripotency state in hESCs is 
artificial as compared to the human development. This can be a further explanation for the 
different behavior of derived hESCs (38). 
2. Induced pluripotent stem cells (iPSCs) 
Although natural dedifferentiation of adult cells sometime occurs in vertebrates, it apparently 
never achieves a pluripotent state (11). Yamanaka et al. succeeded in reprogramming a somatic 
cell to generate PSCs by utilizing retroviral transduction of Oct4, Sox2, Klf4 and c-myc , first in 
mice and later also in human (6, 39). The successful possibility of the generation of iPSCs was 
based on three important findings in research over the last decades. First, the technique of 
somatic cell nuclear transfer (SCNT) has shown that different somatic cells keep the same genetic 
information as early embryonic cell. Gurdon successfully cloned a frog by using intact nuclei 
from a somatic cell and fused it with an enucleated egg. With the same technique, the sheep 
Dolly was developed having the same genetic background as the mammary cell donor (40). 
Those cloning results demonstrate that the genome of a fully differentiated cell has the capacity 
to support the development of an entire organism. Nevertheless, this technique is challenging and 
not ideal for genetic studies. Second, the technique of deriving and culturing ESCs arose and 
improved. Third, a whole network of transcription factors involved in the maintenance of cellular 
identity during development was discovered. They act by switching on specific genes, while 
lineage-inappropriate genes are suppressed (reviewed in (41)).  
Initially Yamanaka et al. screened 24 transcription factors that might have an influence in the 
maintenance of pluripotency. They systematically narrowed the necessary factors down until they 
landed on four transcription factors, Oct3/4, Sox2, c-Myc, and Klf4. These were sufficient to 
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induce the development of stem cell-like colonies (39). This approach has later been successfully 
adapted to human cells (6). In the past years, different reprogramming methods have been 
developed to derive iPSCs with an increased efficiency in reprogramming cells. First retro-or 
lentiviral vectors were used to deliver the mentioned transcription factors, but the risk exists that 
their transcriptional activity remains in the pluripotent cells. Thus, several other techniques were 
established to generate iPSCs while avoiding the integration of any viral vector into the genome 
of the treated cells, such as nonintegrating viral vectors (e.g. sendai-virus) (42).  
IPSCs cells are mitotically active and have the capacity of self-renewal. Moreover, they can 
differentiate in vitro into derivates of all three germ layers and they can build teratoma in vivo. 
They have the same morphology than the hESCs and can be cultured in the same conditions. 
Their pluripotency status is usually characterized by performing the same tests than for hESCs 
(41, 43, 44).  
3.  iPSCs versus hESCs 
There are two main advantages existing of the iPSCs technology towards the hESCs. First, no 
ethical issues are existing in the generation of hESCs, where an embryo needs to be destroyed in 
order to isolate cells. Second, in the field of cell replacement therapy, the problem of the immune 
incompatibility between the donor cell and the recipient, which could lead to the rejection of the 
transplanted cells, can be eliminated by using patient-derived iPSCs (45). However, the debate 
still continues to what extent iPSCs recapitulate the characteristics of hESCs. By comparing the 
transcription profile of iPSCs and hESCs, some differences were encountered. Some show that 
the profiles are nearly identical with only a small group of genes being expressed differentially 
(46). Other comparisons show that some differences in the expression profile of iPSCs and ESC 
exist, but are not consistently observed in all iPSCs lines. By investigating more into detail the 
individual reprogramming experiments, significant difference between iPSCs and hESC can be 
observed that can be referred to the reprogramming step where (i) iPSCs not efficiently silenced 
all the genes from the somatic cell from which they derived and (ii) iPSCs failed to induce some 
ESC specific pluripotency genes (47). This leads to the assumption that iPSCs may have an 
epigenetic memory. Two studies analyzed the epigenetic memory, referred to DNA methylation 
and histones modifications  of mouse iPSCs and they could show that iPSCs, which were 
differentiated back to the cell of origin showed an advantage over another differentiated cell from 
another lineage (48)(49). This phenomenon could only be observed during early passages (P4-P6) 
of iPSCs indicating that the reprogramming process needs a longer time to be accomplished as 
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expected. Moreover, the step of reprogramming using specific transcription factors may lead to 
spontaneous aberrations in the genome since most of these genes are associated with neoplastic 
development (50). Finally, iPSCs and hESC show also variations in their capability to 
differentiate, the former exhibiting in some cases lower performances. Also in this context, it is 
difficult to compare the potential of iPSCs to differentiate into specific cell type due to different 
culture conditions and various differentiation protocols. However, by a direct comparison of 
differentiation potential between iPS and hESC, the outcome of differentiation can be evaluated 
in different ways; by scoring the efficiency of differentiation by quantifying the obtained cells 
using a specific marker or by assessing the quality of the differentiated cells. IPSCs and hESCs 
show variations, either the show the same or in some cases as well lower performance of 
differentiation. The possible inferior performance of iPSCs could be explained by a higher 
tendency for aberrations, which subsequently might influence cell perception of external 
differentiation signals. All these differences may mainly arise due to incorrect reprogramming 
behavior although the efficiency of reprogramming may still be optimized (47). 
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C. Uses and promises of the hPSC technology 
A main challenging aspect in biology is the understanding of the development of the human 
body. Furthermore, disease associated prevention and treatment of diseases are of a major 
interest. Much knowledge about human development is being extrapolated from model organisms 
which gave us an insight into the general principles of development and signaling pathways, such 
as the drosophila (e.g. discovery of the hox genes in controlling the body plan) (51). 
The mouse is the primary model organism for the study organ development in humans. Both the 
mouse and the human genomes share a high percentage of similarity. However, they differ in 
several species-specific genes and in some organ functions. Moreover, important events of 
embryonic development are also different, in particular during gastrulation. Subsequently, these 
dissimilarities lead partly to the disability of recapitulating some human diseases in the mouse 
model. The same genotype may be lethal in one species whereas in the other it may be viable. For 
that reason, it is essential to conduct some biomedical research directly in human models, which, 
in the case of embryonic development, is mostly limited to in vitro systems. HPSC have two 
major advantages to be suitable for human development studies and disease modelling. Since 
they are primary cells, they have the potential to self-renewal and they have the capacity to 
differentiate into every adult cell type. These features enable the study of the relationship 
between genotype and phenotype and to obtain a high number of cells for further purposes like 
cell therapy (51, 52). 
1. Model for normal human development 
A model for the early embryogenesis is the embryoid body formation (see D.3.). Briefly, hPSCs 
are cultured as aggregates in suspension and are able to differentiate spontaneously into cells of 
the three germ layers. The EB formation is mostly used as the initial step for the differentiation 
into any specific cell type (53). Expression patterns in human EBs demonstrate that several genes 
are activated which are involved in the early embryogenesis, the gastrulation and the formation of 
the germ layers. Therefore, the EBs are a useful model to understand the mechanisms that drive 
the human embryogenesis. As an example, the study with EBs illustrated that NODAL and 
LEFTY, which belong to the transforming growth factor (TGFß) superfamily, are involved in the 
gastrulation process. Inhibition of NODAL/LEFTY lead to the disruption of mesodermal 
differentiation (51). 
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HPSCs are also used to mimic cell fate specification via direct differentiation. To mimic the 
tissue specific development during embryonic development, first the hESCs must be 
differentiated into the three germ layers and then further to any specific cell type through the 
addition of recombinant growth factors and/or small molecules. For example, it is known that 
hESCs are exposed to activin A to differentiate into endoderm, to BMP4 and activin A for 
mesodermal differentiation and to inhibitors of BMP4 and WNT signaling to be able to 
differentiate into the ectoderm. In those tissues, in which no specific knowledge is available, the 
in vivo environment can be recapitulated using cells isolated from an environment in which the 
desired cell type is present. For example, a study illustrated the following; they wanted to 
understand why in the inner ear lost hair cells could not be regenerated. First, they differentiated 
mESC into the ectoderm and by the exposure to ear-related factors, otic progenitor cells were 
built. They further plated these progenitors on stromal cells of the ear to induce the formation of 
hair cells (54).  
HPSCs also offer opportunities to understand developmental mechanisms. Studies have been 
carried out to investigate the role of the signaling of TGFß during pancreatic development. By 
using hPSCs, they could show that TGFß inhibits the differentiation of pancreatic progenitors 
into the lineage that gives rise to the ß-cells of the pancreas (reviewed in (51)). 
2. Disease modelling and drug discovery 
Apart from studies of the normal development, hPSCs are also utilized to study abnormal 
development and specific diseases. In a first step, a cell line need to be established carrying the 
defect of interest, which can be used to investigate the phenotype of a particular disease. 
Different models exist to generate genetic disorders (Figure 4).  
HPSCs carrying genetic disorders can be generated from healthy or aberrant cells. Isolated 
hESCs from healthy donors may be genetically modified at a specific locus so that a disease 
phenotype can be further characterized. Additionally, hESCs can develop spontaneously 
chromosomal aberrations during culture. These cells can be isolated and further investigated, 
such as cells with the karyotype causing the turner syndrome, displaying monosomy X. HESCs 
may also be isolated from human embryos carrying specific mutations or aberrations, which were 
identified by pre-implantation genetic diagnosis (PGD) or pre-implantation genetic screening 
(PGS). These embryos, which otherwise would be discarded due to the diagnosed abnormality, 
may be used as in vitro models for particular disorders. Since only a reduced number of disorders 
can potentially be identified by PGD or PGS the ability to reprogram somatic cells yield to new 
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possibilities in the field of disease modelling. The technique of somatic cell nuclear transfer 
(SCNT), whereby a nucleus of a somatic cell can be reprogrammed and subsequently implanted 
into an enucleated oocyte allows the derivation of hESCs from patient cells.  
 
Figure 4: HPSC carrying a genetic disorder can be generated by using healthy or aberrant cells. Either the 
isolated hESC acquire spontaneous aberration during culture or the hESC can be genetically edited. The cells 
can be also used from a carrier of a genetic disease. Either disease-specific hESC cells are identified during 
PGD or PGS before in vitro fertilization is carried out. Another possibility is be reprogramming of a somatic 
cell of a patient by SCNT of hESC or by generating iPSCsC (adapted from (52)). 
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The alternative process is the reprogramming of a somatic cell into iPSCs. The reprogramming of 
patient cells has the advantage that the iPSCs from multiple patients can be easily generated and 
enables the analysis of similar mutations but with different genetic backgrounds. Several 
laboratories generated successfully different disease-related iPSCs from fibroblasts of patients 
carrying a specific mutation. The presence of the mutation was confirmed in the newly generated 
iPSCs line. Phenotypes of neurological disorders were the first diseases that could have been 
recapitulated in vitro due to the extended knowledge and demonstration of normal neuronal 
development. Amyotrophic lateral sclerosis (ALS) was modelled by generating iPSCs of dermal 
fibroblasts taken from two patients, which are both heterozygous for the L144F mutation in the 
superoxide dismutase gene. iPSCs were differentiated into motor neurons and investigated for 
different factors (reviewed in (52)). 
As reported, the disease modelling helps first to understand the cellular and molecular 
mechanisms related to it. Second, it enables to approach particular drug screening strategies using 
hPSCs. When a specific phenotype is identified to be treated, two main approaches are used to 
identify potential beneficial drugs. Briefly, an iPSC, which carry a disease-specific genetic 
aberration, can be further differentiate to the disease-affected cell type (e.g. neurons for 
neurodegenerative diseases). The candidate drug approach contains a small number of 
compounds that are investigated on affected cells. This strategy is used when already knowledge 
about a disease exists, such as one specific pathway, which is known to be responsible for the 
induction of a specific disease. Thus, a defined set of drugs is tested to identify the most potent 
therapy. The effect of existing drugs is also validated and confirmed in the iPSCs models. The 
high-throughput screening (HTS) approach is based on investigating the potential effects of more 
than 1 million compounds. However, with this method, it needs to be guaranteed to re-evaluate 
the phenotype again specifically, like for example when a disease has an electrophysiological 
defect. A large number of cells are needed to test a wide range of compounds. Drug discovery in 
neurological disorders is more progressed than in other medical fields. So far, 25 neurological 
diseases, for which iPSCs-derived neural cells have been develop to model the disease and were 
used to screen potential drug components. However, most of these diseases are linked to 
monogenic or chromosomal aberrations rather than to complex genetic disorders. Moreover, it 
needs to be considered that the approach of using iPSCs for drug development is still at the very 
beginning and the first step of a long phase until the identified drug can be used on the market for 
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treating patients. The future aim of hPSC-based therapies is to model every genetic disease, even 
complex ones. These current existing approaches have already confirmed the high value of 
hPSCs in modelling and treating various diseases (reviewed in (52)). 
3. Regenerative medicine 
One promise of iPSCs cells is the replacement of diseased or injured cells within specific organs.  
The main challenge of this approach is the ability to provide iPSCs cells or iPSCs-derived cells to 
the target tissue while maintaining the organ viable and functional. There are two ways how the 
cells can be delivered into the affected organs; (a) via intravenous injection with the expectation 
that they will return to the concerned organ and can be engrafted successfully. Thereby cells are 
mostly injected naked in a buffer with the disadvantage of a high rates of cell death (45), or (b) 
via local delivery of the cells during open surgery into the organ. In this situation, injectable or 
implantable scaffolds are used to support engraftment and cell survival (tissue engineering 
approach). There are several applications being used, in which pluripotent stem cell derivates 
(such as cardiomyocites and A9 dopamineric neurons) are already in phase 1 or 2 clinical trials. 
A phase 1 clinical trial is the first step towards the development of a new treatment in humans. In 
this phase, the maximal amount of treatment that can be given to a patient is evaluated. In the 
phase 2, more persons are recruited to determine the effect of the tested drug. As an example, ES 
cell-derived cardiomyocytes were used to repair cardiac muscle damage after myocardial 
infarction. A patient, also receiving a coronary bypass operation was grafted in the infarcted area 
with the derived cardiomyocyte progenitors. The cells were embedded in fibrin to enable the 
integration of the grafted cells into the heart tissue. The symptoms of the disease significantly 
improved after 3 months and contractibility was observed in the previously kinetic myocardial 
region. However, it is not yet clear if it is due to the bypass operation or the engraftment (55). To 
reach the step of the clinical study, it is indispensable that the safety of PSC-derived cells is 
properly tested (e.g. for chromosomal stability and mutations in oncogenes) in the preclinical 
phase to avoid any adverse events in the patients (56). 
4. Prospect of human organ growth inside animals 
One future goal of stem cell technology is to grow functional and transplantable tissue or full 
organs in vitro. An important first step towards this approach was established by the formation of 
a human-animal chimera. First, a mouse-rat chimera was built using the CRISPR-CAS9 genome 
editing tool to delete specific genes which are responsible to build heart, pancreas or eye in the 
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mouse blastocysts. Subsequently, they introduced rat PSCs into the embryo and the resulting 
mouse offspring could develop the organs from rat stem cells. Surprisingly the rat stem cells were 
able to build a gall bladder in the mouse, even though in the rat this organ is not developed 
anymore over the last million years. This shows that the gall bladder is not developed anymore 
because the potential remains hidden by a rat-specific developmental program. Next, they 
induced hiPSCs into a pig blastocyst. They chose this animal since the organ size of pigs 
resembles that of humans. Several types of hiPSCs were tested to be implanted in the blastocyst 
of the pig, like naïve, intermediate and primed hiPSCs. The intermediate hiPSCs turned out to be 
the most suitable ones since the embryos at a particular stage managed to survive the 
experimental procedure. They could successfully build a human-pig chimera embryo, which was 
subsequently implanted into a sow and developed for 28 days. With the help of fluorescence 
tagging they could detect within the pig embryo about 1 living human cell in 100’000 pig cells. 
Next, they aim to improve the efficiency and push the human cells into the formation of 
particular organs using the CRISPR-CAS9 method, as applied for the mouse-rat chimera 
(reviewed in (57)). 
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D.  Characterisation of hPSCs 
Multiple criteria have been proposed to evaluate the pluripotency status of newly generated 
hPSCs. In general, PSCs are verified by their status of undifferentiation investigating the 
morphology, cell surface phenotype and gene expression profile and by their capacity to 
differentiate into various cell types assaying the differentiation potential in vitro and in vivo. 
Furthermore, euploid karyotype, epigenetic status and extended proliferative capacity are 
essential criteria to be characterized. Nevertheless, these assays vary in specificity with which 
they analyze the state of pluripotency (58, 59). 
1. Assessment of hPSC morphology 
hPSCs acquire a typical morphological appearance when they are grown in culture. The cells 
typically have a round shape with a large nucleus, large nucleoli and a scant cytoplasm. They are 
arranged in compact colonies with distinct boarders and sharp-edges. The morphology of the 
newly derived hPSCs can already be used as a first screen during the colony selection (60). 
2. Markers of pluripotency 
A widely-tested panel of markers of the undifferentiated state of hPSCs exist. The international 
stem cell initiative has been conducted a study in which they characterized 59 hESCs lines from 
17 different laboratories worldwide. Even though there is a huge diversity in the techniques to 
generate and maintain hESC lines they could identify similar expression patterns for a number of 
pluripotency markers (61). 
A number of transcriptions factors (TF) playing a crucial role in regulating the maintenance of 
self- renewal were identified, such as octamer-binding transcription factor 4 (Oct4), SRY (sex 
determining region Y)-box 2 (SOX2) and Nanog. These TFs are known to be the key regulatory 
genes to maintain pluripotency and self-renewal and act cooperatively with each other in a 
complex way (62). This network has the ability to positively regulate genes needed for 
maintenance of pluripotency state while repressing genes encoding lineage-specific regulators. 
When any of these master transcription factors is no longer expressed to keep pluripotency the 
differentiation program will be initiated (63). Oct4 is a member of the POU-homeodomain family 
and is a key player to sustain totipotency or pluripotency and is highly expressed in the ICM of 
the blastocyst (64, 65). A balanced Oct4 level is required to maintain the pluripotency state of 
cells cultured in vitro (66). In addition, Oct4 plays a role in the regulation of gene expression 
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networks. Depending on its expression during development it has an influence on the lineage 
commitment to early endoderm and mesoderm by overexpression whereas a repression of Oct4 
leads to a loss of pluripotency and de-differentiation to the trophectoderm (67). SOX2 belongs to 
the SOX transcription factors and is also regulating the pluripotent state as well as the 
differentiation to different cell types during development (68). SOX2 controls the differentiation 
to specific cell types, such as the nervous system and anterior foregut endoderm during early 
development (69, 70). It further regulates the progenitor cells in adult tissue of the brain and 
trachea (71, 72). Nanog is also known to be essential for pluripotent cell development and 
maintenance.  Furthermore, it controls the epiblast versus the primitive endoderm decision in the 
blastocyst (66). Since these TFs play a crucial role in the guarantee of the undifferentiated and 
self-renewal status, they became important markers for the identification of the pluripotency 
status when a newly derived hPSC line was generated. 
Furthermore, glycolipids and glycoproteins that were originally identified on embryonic 
carcinoma cells became later biomarkers for pluripotent stem cells, such as SSEA-3, SSEA-4 
TRA-1-60 and TRA-1-81 (73).  Interestingly, after the induction of differentiation into cell of the 
three germ layers each marker show a different kinetic of disappearance. For example, OCT4 and 
TRA-1-60 were the first markers that are down-regulated whereas Nanog is detectable for a 
longer time period after the initiation of differentiation (74).  
The alkaline phosphatase (AP) is another key marker to identify pluripotency. AP is an enzyme, 
which is highly positive in the ICM. As soon as the differentiation has started the AP expression 
it is downregulated. Thus, high AP activity is related to a high number of PSCs (75) 
These markers are the most commonly used in stem cell research and are tested both on RNA and 
protein level by qPCR and immunohistochemistry respectively. However, several arrays exist 
with specific genes that are involved in the maintenance of pluripotency and self-renewal and are 
often used to have a deeper insight in the expression pattern of the new hPSC lines (76).  
3. In vitro differentiation- embryoid body (EB) formation 
When specific factors that maintain stemness of the hPSCs are removed during culture (e.g. 
ßFGF), the cells spontaneously differentiate into cells of the different germ layers. By 
dissociating hPSCs from the colonies and after their transfer in suspension, the cells are able to 
aggregate and build spherical three-dimensional embryoid bodies (EBs) (77). Due to cell to cell 
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interactions the cells within an EB are able to differentiate spontaneously into derivates of all 
three germ layers. With this possibility to differentiate, the EBs recapitulate the early embryonic 
development. The EB formation is the most commonly used in vitro assay to prove the capacity 
of the hPSCs to differentiate (53).   
The first indication that an EB starts to differentiate is the spontaneous formation the primitive 
endoderm (PE) on the surface of the EBs. The cells of the PE further differentiate into visceral 
and parietal endoderm. These generated cells build a membrane that separates the PE cell layer 
on the surface from the remaining undifferentiated cells. Cells that are not directly in contact with 
this membrane undergo apoptosis leading to the formation of central cystic EBs. During further 
differentiation within the EB, different phenotypes of all three germ layers arise (77).  
However, the major challenge of this assay is the heterogeneous differentiation capacity of the 
EBs. The differentiation outcome is highly dependent upon the quality of the EBs that is mainly 
determined by their individual size (78, 79). The size of an EB is primarily depends on the 
number of hPCS within each single EB and subsequently depends on the cell-cell interaction 
(80). While too small EBs do not survive the differentiation process, too big EBs undergo central 
necrosis and become cystic due to reduced access to mass transport (81).  
There are two principles to assess the differentiation potential of hPSCs. EBs are either used to 
prove the capability to differentiate spontaneously into the three germ layers (so called stochastic 
EBs) or they are used as intermediate for the direct differentiation towards specific cell types of 
the three germ layers such as neural and cardiac cells. Depending on the approach that is 
implemented, the uniformity of the size of the EBs is crucial for the reproducibility of the 
differentiation process. By contrast, for the illustration of diverse tissues derived from the three 
germ layers the ability to build EBs of different sizes poses advantage (82). 
Numerous approaches have been developed to induce EB formation (83). To induce stochastic 
EBs, cells are put in suspension culture in dishes with hydrophobicity. Thereby the seeded hPSCs 
don’t attach to the surface and naturally stick to each other and build aggregates. The 
composition of the culture medium that is used has an influence in the viability and the 
differentiation process of the EBs. It was reported that EBs cultured in a lower glucose 
concentration than normally in combination with the growth factor ßFGF increased the variability 
of different tissue-like structure within an EB (84).  
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However, in order to generate specific tissue types through the formation of EBs, a different 
culture system must be applied. The homogenous size of the EBs has been demonstrated to 
simplify the differentiation process. Different methods have been developed to form EBs with 
defined sizes. The hanging drop (HD) method provides the hPSCs a good environment to build 
EBs. The number of cells that aggregate in a hanging drop is more controlled by an exact number 
of cells of the initial population to be hung as a drop from the lid of a petri dish. One EB per drop 
will be formed from a predetermined number of hPSCs in a defined volume of liquid leading to a 
more homogenous distribution of the size of the produced EBs. 
After 2 days, the EBs are placed in suspension for further differentiation. This method has the 
disadvantage of limited preparation of EBs due to the limited volume of the hanging drop. EBs of 
homogenous size are built in a 96 well-plate. Similar to the HD culture, one EB is composed of a 
predetermined number of hPSCs per well but by contrast it enables medium exchange and the 
management of a large volume of cell suspensions. However, the number of cells to build an EB 
affects the differentiation of the resulting EB. Another alternative technique to produce EBs is the 
stirred flask method, in which the cells are cultured in a special flask with a magnetic stirring to 
ensure a continuous rotation of the culture medium. Compared to the static culture, the 
aggregation of the cells is easier and the cells are exposed to a better gas exchange as compared 
to the static culture. It has also the advantage to scale up the EB production (80, 82, 84, 85). 
To verify the germ layer formation of EBs, the expression of germ layer specific genes and the 
demonstration of tissue-like structures must be studied. Upon EB differentiation, gene expression 
studies allow the identification of the germ-layer specific markers and the lack of pluripotency 
genes. Histology later allows a more detailed assessment of differentiation into various tissues 
(82). 
4.  In vivo differentiation- teratoma formation 
4.1 Definition of a teratoma 
The name “teratoma” has its origin in the Greek word “teras” which means “monster” (86). By 
definition, a teratoma contain tissues derived from all three embryonic germ layers, the endoderm 
mesoderm and ectoderm, like hair, teeth and bone (87). This type of tumor belongs to the non-
seminomatous germ cell tumors (N.S.G.C.T). All the tumors of this category are the result of 
abnormal development of pluripotent cells (Germ cells and embryonic stem cells). Teratoma 
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which derive from germ cells are mostly developed in the gonads (testis and ovary). In contrast 
teratoma derived from embryonic stem cells occur mostly in the sequestered midline of the 
human body (88). 
4.2 Clinical implications of teratoma 
Mature teratomas consist of various differentiated somatic tissue that are foreign of the particular 
tumor site. Immature teratoma are composed of immature structures or incompletely 
differentiated tissues, like primitive neuroectodermal structures. Furthermore, the degree of 
immaturity correlates with the proliferation rate (89, 90). 
Regardless of location of the body, the grade of maturity of the teratoma is assessed according to 
a cancer staging system, which is important to grade the severity of the tumor, which gives 
indication for surgery or radiotherapy. The teratoma is classified using the grading system 
outlined by Gonzales-Crussi in 1982 (91): 
Grade 0: Mature (benign) 
Grade 1: immature, probably benign 
Grade 2: immature, possibly malignat (cancerous) 
Grade 3: Frankly malignant. If the teratoma is frankly malignant, the tumor is a cancer for which 
additional cancer staging may be performed. 
Furthermore, a teratoma can be classified by its content; one distinguishes between solid 
teratoma, containing only tissues from cystic teratoma, contain only pockets of fluid or semi-
fluid such as sebum, or fat; and mixed teratoma containing solid and cystic parts. (88, 92)) 
4.3 Experimental teratoma 
The most stringent proof of pluripotency is the generation of chimera via germ line transmission 
as it is applied for testing pluripotency of mPSCs. Thereby, mPSCs are injected into a blastocyst 
of a wild-type mouse and the first resulting breed is called chimera. It is defined as an organism 
with genetically different cell populations derived from more than one fertilized egg (93). 
However, this test of forming a human chimera is not applicable for hPSCs due to ethical 
concerns (61, 94). That is why the spontaneous differentiation of hPSCs in vivo is assessed by 
teratoma formation in immundeficient mice, which is defined as the gold standard for the proof 
of pluripotency (95, 96). Essentially hPSCs are injected into different transplantation sites (such 
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as testis, subcutaneously, capsula of the kidney) in immune-deficient mice until a potential 
tumour is developed.  
Up to now, the histogenesis of the teratoma is poorly understood but the cells mimic the post-
implantation early embryonic development.  The tumor consists of different somatic tissues with 
various degrees of maturation. Some teratoma show organized structures of adult tissue but most 
contain structures resembling early stages of development, such as neural rosettes (97). HPSCs 
are considered as pluripotent when the derived tumor is identified as a teratoma by displaying 
various different types of tissues deriving from all three germ layers (endoderm, mesoderm and 
ectoderm) (98).  
4.4 In vivo teratoma assay- state of the art 
The method of inducing a teratoma differ widely among different research groups in several 
aspects, such as the preparation of cells, the number of transplanted cells, the choice of the 
transplantation site and the incubation time (99, 100). One study that was performed in 2009 to 
investigating the susceptibility to form hESC-derived teratomas according to the transplantation 
site (kidney capsula, muscle, subcutaneous space, peritoneal cavity, testis, liver and epididymal 
fat pad) in SCID mice. The effect of matrigel was assessed as well. Interestingly, in all generated 
tumors within 8 weeks a pronounced liquid cyst, interfering with histological analysis were 
detected. They found out that the most experimentally convenient and reproducible way to build 
a teratoma was the intramuscular injection of hESCs without matrigel. Another research group 
published an in vivo teratoma assay which showed the most reproducible method is based on the 
subcutaneous injection of 100`000 cells together with inactivated feeder cells and Matrigel into 
an immune-deficient mouse. The assay was highly reproducible and 100% efficient.  As we can 
see from these two examples, the techniques to ensure a teratoma vary a lot. It has also been 
shown that the numbers of cells to induce a teratoma is varying among different manuscripts; for 
example, a range between 3000 to 5 million of hPSCs exists for testicular injection. In case the 
cells grow on feeder layers, no single cells can be generated. As a result, the number of injected 
cells are vaguely described as being “50 clumps of 300 cells” Since these great number of 
variables exist in generating a teratoma in vivo, one cannot be sure if the failure to induce a 
teratoma with the newly derived hPSCs is due to inappropriate conditions of the assay or due to 
an abnormality of the generated hPSC line (reviewed in (101)).  
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Even if the in vivo assay is presented in the manuscript, mostly the information reported for 
generated a teratoma remain utterly vague. The number of animals used for an experiment is 
rarely reported and the failure to produce teratoma is almost never explained (101).  
In most cases the generated teratoma is assessed by histochemical analysis using the conventional 
Hematoxylin and Eosin staining. The generated structures that are derived from all three germ 
layer are identified mostly by a pathologist who further classifies them as derivates from 
endoderm, mesoderm and ectoderm. Most of the studies report at least one tissue per germ layer, 
such as gastrointestinal glands for endoderm, cartilage for mesoderm and neural tubes for the 
ectoderm (102-105). In some cases, specific markers are tested by immunohistochemistry to 
identify differentiation into the three germ layers, such as smooth muscle showing smooth muscle 
cells derived from the mesoderm, ßtub3 detecting young neurons from the neuroectoderm and 
different types of cytokeratin to demonstrate the presence of epithelial cells (106). 
This summary of the inconsistencies in the methodology used and in the poor reporting of the 
results show that there is a need of a standardization of the in vivo teratoma assay, which is 
supposed to be the gold standard for demonstrating pluripotency of hPSCs (99). 
5.  Karyotype 
A diploid karyotype is another condition to be fulfilled for a newly generated hPSC line. Once a 
new hPSC line is established, it is expected to stay chromosomally stable. HPSCs are often 
karyotyped using standard GTG banding metaphase spreads, comparative genomic hybridization 
(CGH) but also more precise techniques like single-nucleotide polymorphism (SNP) arrays (107, 
108).Chromosomal changes of hPSCs in long-term culture have been reported several times by 
various laboratories (109-111). In hESCs the most reported aberrations are the gain of 
chromosomes 12 and 17, duplication of 1q11q32 and 20q11.21 region or the aneuploidy of 
chromosome (109, 112). These mutations confer often to proliferation advantages, higher culture 
adaption and resistance to apoptosis. It has been reported that the quality of the blastocyst has an 
impact on the chromosomal status of any newly derived hPSC line. In some cases, aneuploidy 
has been observed already at the stage of the blastocyst (113). For iPSCs two different 
aberrations were described such as the gain of trisomy of chromosome 8 and 12 but also deletion 
of chromosome 8 and 17. Furthermore the amplification of portions of chromosome 1, 17, or 20 
is frequently observed. It is not yet fully clear whether these chromosomal variations in iPSCs 
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originate at an early stage or later during culture or whether they are caused by the 
reprogramming process (108, 114). Chromosomal aberrations in iPSCs can also occur during the 
culture of the somatic cells, which underwent several cell divisions before they were transformed 
to iPSCs (115). 
The method of passaging the hPSC has been shown to have an effect on chromosomal changes. 
The mechanical technique by cutting the colonies into small pieces with a blade has turned out to 
be less aggressive than enzymatic passaging, therefore the euploid population may be better 
preserved (116). It has also been shown that hPSCs with a higher passage are more vulnerable to 
karyotypical changes than hPSCs with a lower passage. However, some generated hPSCs are 
more prone to chromosomal changes already at early passage than others (117). Due to these 
facts, it is important that a karyotype is performed more regularly during long-term culture to 
ensure that the hPSC line remains chromosomally stable. This is important to test since the 
existence of chromosomal abnormalities in hPSCs is often associated with carcinogenesis and 
impaired in vitro and in vivo cellular behaviour (115). 
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E. The tumorigenicity of hPSCs 
HPSCs share many characteristics of tumor and cancer cell lines (106, 118). Both have a fast 
proliferation rate, a tendency of genomic instability, a high telomerase activity and similar gene 
expression patterns (50). 
The acquisition of tumorigenic potential of hPSC has to be considered especially in regenerative 
medicine (115).  Since hPSCs have cancer-cell characteristics it is challenging that these cells 
stay normal in their behaviour. They are able to transform their genetic background during long-
term culture and may turn to aneuploidic hPSCs (see D.5). It has been shown that the abnormal 
cells tend to give rise to a teratocarcinoma in vivo and not as it should, to a teratoma.  A 
teratocarcinoma is classified as a germ cell tumor that is composed of tissue elements from all 
three germ layers, but it also contains undifferentiated malignant cells, known as embryonal 
carcinoma cells (119). 
Not only aneuploidic hPSCs can result in a teratocarcinoma. It has been reported that mESCs 
with a normal karyotype build a teratocarcinoma in immune-incompetent mice. IPSCs are 
generated by reprogramming a somatic cell by the use of four transcription factors OCT4, SOX2, 
c-Myc and KLF4. These factors are also known to be highly expressed in different types of 
cancer (120, 121). Several approaches have been performed by generating hiPSCs without c-Myc 
or with combining the reprogramming with chemical inhibitors. In comparison to hESCs they 
show a higher tendency of acquiring chromosomal abnormalities (122, 123).  
In consideration of the future clinical use of these cells, the tumorigenic potential of a generated 
hPSC line needs to be investigated more deeply. Newly derived hPSCs should be tested for the 
presence of specific undifferentiated markers after differentiation. By assessing the possibility of 
a teratoma formation one has to investigate more into detail the characteristics of the generated 
tumor, more specifically whether it may turn to malignancy. Additionally, karyotype analyses 
should be conducted not only after the derivation of an hPSC line but also during culture before it 
is used for patient treatment (76). 
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F. Perfusion-based bioreactor culture system  
A bioreactor is defined as an engineered device that supports biological processes under defined 
and controlled conditions. It is a closed environment with a stable condition such as pH, 
temperature, nutrient supply and waste removal. Bioreactors offer the possibility to scale-up, 
which improves the reproducibility and cost-effectiveness (124, 125). To generate a 3D tissue-
like structure in vitro several requirements are necessary; cells need to be incorporated with cell-
to-cell interactions on a 3D scaffold, which act as a template for tissue formation by providing 
mechanical stability and regulating cell function. The cell-scaffold construct needs to be under 
suitable conditions so that necessary nutrients can support the tissue differentiation and 
maturation (126, 127).  
An ideal scaffold should act as the natural in vivo extra cellular matrix (ECM) imitating its 
biochemical and biomechanical property. In particular, natural scaffolds are composed of similar 
macromolecules property as the ECM and are based on different types of proteins such as 
collagen and fibrin among the most common. Collagen I is the most abundant protein in the 
mammalian body and therefore it is the most widely used natural scaffold (128).  
Cell seeding on scaffolds is the first essential step to ensure tissue formation. The cells need to be 
seeded with the highest possible efficiency. It has been reported that manual cell seeding mostly 
leads to irregular cell distribution and poor cell integration into the scaffold. With perfusion-
based bioreactors, the cell seeding efficiency can be more ensured. 
The perfusion provides a higher mass transfer to the cells to support larger viable and uniform 
tissue and to avoid necrosis in the inner part of the scaffold (129, 130). Thereby a homogenous 
cell distribution within the scaffold followed by tissue formation and growth within the scaffold 
can be guaranteed for prolonged times (127, 131, 132).  
Different types of perfusion-based bioreactors have been demonstrated to ensure an efficient cell 
seeding and reduction of external mass-transfer limitation (Figure 5) (125). The spinner-flask 
bioreactor ensures an appropriate cell seeding via convection (Fig.5a) while the rotating-wall 
vessel bioreactors guarantees a high mass transfer with low shear stress (Fig. 5b). In the hollow-
fiber bioreactor, the medium perfuses either through or around the semi-permeable fibers which 
successfully maintain highly metabolic cells (Fig. 5c). The direct perfusion bioreactor allows 
uniform cell distribution by medium flowing directly through the scaffold (Fig. 5d). 
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Figure 5: Perfusion-based bioreactors for tissue engineering. (a) Spinner-flask bioreactors were used for cell 
seeding into 3D scaffolds and for subsequent culture of the construct. (b) Rotating-wall vessels offer a dynamic 
culture environment to the construct, with high mass-transfer and low shear stress. (c) Hollow-fiber bioreactors 
are used to enhance mass transfer during cell culture of highly metabolic and sensitive cells. (d) Direct 
perfusion bioreactors in which medium flows directly through the scaffold, often used for seeding and culturing 
of constructs (adapted from (125)). 
 
The quality of the generated tissues under perfusion also depends on the applied flow rate. 
Different magnitudes of flow-mediated shear stress exposed to the cells have an impact to the 
generated tissue. For example, higher magnitudes of shear have been correlated with increased 
mineralized-matrix production by bone-marrow of cells. Moreover, a scaffold with a 
homogeneous distribution of pores has been shown to control more precisely the shear stresses 
over time. In this context, it is evident that the scaffold used for the approach of tissue generation 
should not be limited to biocompatibility but also in the evaluation of pore structures, which must 
be adapted to particular flow conditions (125, 133). 
The mass transport of oxygen in tissue cultures is crucial for the maintenance of cell viability and 
function. Moreover, it could be demonstrated that the differentiation stage of various cells can be 
changed by applying different oxygen levels during culture (e.g. 5% O2 versus 20% O2 to 
chondrocytes). Thus, it is evident to quantify the level of oxygen within the perfused tissue to 
make sure that a specific flow rate supply sufficient oxygen (133). 
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Computational fluid dynamic (CFD) softwares have been developed in the past years which are 
powerful tools to calculate the appropriate flow rates, shear stresses and mass transport within a 
construct (125). 
Bioreactors not only offer the possibility to generate tissues but also acts as a 3D culture model to 
mimic in vivo environment (125). It is also a platform to regulate the stem cell microenvironment, 
the so-called “niche” which affects the stem cell fate (134). Moreover, this system is promising in 
the field of disease modelling and drug discovery, as for example in cancer research by 
mimicking the tumorigenic development to further test specific anticancer compounds (129, 135) 
. Moreover, it has to be considered that the bioreactor approach is a promising new model system, 
which in combination with hPSC cells can lead to a further understanding of human 
developmental aspects. All these different approaches using the bioreactor leads as well to a 
tremendous reduction of animal use, since the in vivo tool has been used so far to model human 
diseases with the aim to understand the mechanisms and subsequently the effect of different drug 
compounds (51). 
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Aim of the thesis  
The generation and use of human pluripotent stem cell (hPSC) lines are expected to have a substantial 
impact on medical and biological science. Their capacity of unlimited self-renewal on one hand and of 
broad differentiation capacity into any cells types on the other hand make them powerful and versatile 
tools to investigate early human development and diseases. Moreover, with the increasing ability to direct 
their differentiation in vitro into selected cell types and to modify them by molecular engineering, 
clinicians hope to use hPSC-derived products for therapeutic purposes. However, different techniques to 
generate new lines are being used and the way of analyzing their pluripotent character varies widely 
between the lines. Furthermore, and maybe consequently, functional, phenotypical and molecular 
differences between lines are observed. Thus, extensive and standardized characterization of hPSCs lines 
might be an important prerequisite to allow stem cells and stem cell technology to fulfill their 
expectations. 
In chapter I I describe the characterization of four hESC lines that we generated and maintained using the 
same protocol. We compared their stemness and differentiation properties and defined their differences, 
despite their maintenance under identical conditions.  
In chapter II I propose the establishment of a perfusion-based culture system to generate a teratoma-like 
tissue in vitro. Teratoma formation in vivo after hPSCs grafting, i.e. the formation of nontumorigenic 
advanced tissues and structures derived from the three embryonic layers, is nowadays the standard to 
prove pluripotency. However, there are many inconsistencies in the protocols used to induce a teratoma in 
vivo and in the way the results are analyzed and reported. For these reasons, we have set up and 
characterized an animal-sparing, more standardized and controlled method to ensure a proper assessment 
of pluripotency, which could be used as an alternative or complementary to the current in vivo teratoma 
formation assay. 
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Chapter I:  
 
„Gene Expression Profiles of Similarly Derived Human Embryonic Stem Cell 
Lines Correlated with Their Distinct Propensity to Exit Stemness and Their 
Different Differentiation Behavior in Culture“ 
Enclosed is the paper published in Cellular Reprogramming, 2014 Jun, 16(3):185-95 
In this paper I contributed to the characterization of the newly derived hESC lines  
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Chapter II:  
 
„Assessment of stem cell pluripotency using an in vitro 3D perfusion-based 
culture model“ 
This chapter contains my main project. The corresponding manuscript is ready for submission in 
a peer-reviewed journal.   
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Assessment of stem cell pluripotency using an in vitro 3D perfusion-based 
culture model 
1. Abstract 
To demonstrate pluripotency status of newly derived human pluripotent stem cells (hPSC), the 
degree of undifferentiation and the capacity to differentiate into the three germ layers both need 
to be verified. The in vivo teratoma assay ranks as the most universally accepted methods to 
ascertain pluripotency. The conventional in vitro method to verify spontaneous differentiation is 
the embryoid body (EB) formation. However, both methods lack standardization and are 
burdened by a high level of variability in both methodology and readout. In addition, the in vivo 
teratoma assay is animal consuming because it requires the use of immune-incompetent mice for 
transplantation of hPSCs. To replace that test, we now evaluated a three-dimensional (3D) 
perfusion-based in vitro culture system (perfused culture). Human embryonic stem cells (CHES6) 
and iPS cells were cultured on a collagen scaffold under perfusion flow. EBs cultured in 
suspension and hPSCs transplanted into immune-incompetent mice were used as controls. 
Results show that perfusion of the scaffold is essential for tissue viability with a high potential of 
structure formation. Comparison of perfused culture with the EBs revealed similar expression 
pattern of differentiation markers of the three germ layers but results were more consistent in the 
perfused culture. The perfused culture system distinguished normal stem cell lines from an 
abnormal cell line (CHES1) by its ability to generate teratoma-like tissue within 3 weeks. Based 
on an established grading system to identify the degree of differentiation of one structure per 
germ layer (intestinal epithelium, smooth muscle and neural tubes) the perfused culture reached 
the same degree of differentiation as the in vivo teratoma at 3 and at 8 weeks of culture in contrast 
to the EB culture. The development of teratoma-like tissue of hPSCs was 90% in the perfused 
culture but only 33% in vivo. Our findings present an animal-free applicable system that can be 
used as a possible pluripotency assay for screening newly derived lines before they will be further 
investigated. This system would bear relevance towards definition of more practical and better 
standardized regulatory guidelines for assessment of hPSCs.Furthermore, it can also be used as a 
model to investigate early human development and further used for drug discovery.  
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2. Introduction 
Human pluripotent stem cells (hPSCs) including human embryonic stem cells (hESCs) and 
human induced pluripotent stem cells (hiPSCs) are characterized by their capacity of self-renewal 
in an undifferentiated state and their ability to differentiate into cells of all three germ layers: 
endoderm, ectoderm and mesoderm (1, 2). Due to their unique capacity and with the advent 
technology for the derivation of hPSCs, these cells are promising for widespread application like 
regenerative medicine, disease modelling and drug development (3). Consequently, it is crucial 
that the pluripotency status of newly derived hPSC lines is properly characterized. 
Multiple criteria have been proposed to evaluate the pluripotency status of newly generated 
hPSCs. In a first stage, the undifferentiated status is assessed by morphological analysis and 
through the expression of distinct markers typical of undifferentiated hPSCs such as Nanog, 
Oct4, Sox2, SSEA4 and TRA-1-81 (4).  
Furthermore, the differentiation capacity is assessed by in vitro and in vivo differentiation of the 
cells into the three germ layers. The gold standard to prove pluripotency is the formation of 
transplanted hPSCs into teratoma in immunodeficient mice (5). A teratoma is defined as a tumor 
consisting of tissues generated spontaneously from all three germ layers (6). Despite the obvious 
eminence of this assay, it is burdened by lack of standardisation. There are no uniform protocols 
for the site of implantation (7), the number of injected cells (8) and the duration of observation 
until teratoma formation (9). Moreover, this assay raises ethical concerns since hPSCs are grafted 
in mice, which induces pain and suffering of the animals used in the assay (10).  
Up to now, the conventional assay for in vitro differentiation, the embryoid body formation 
(EBs), is used to mimic the spontaneous differentiation of the hPSCs in vitro (11). EBs are three-
dimensional aggregates of hPSCs cultured statically in suspension, that are able to differentiate 
into cells of all three germ layers in the absence of any specific growth factor (12). However, the 
quality of the EBs is highly dependent on the culture condition, the number of cells and the size 
of the EBs at onset of culture (13, 14). Due to the high variability of differentiation of each single 
EB cultured in suspension, this method gives rise to  heterogeneous populations in terms of cell 
and tissue morphology (15). For that reason the differentiation potential of hPSCs in vitro is often 
assessed by direct differentiation of EBs into particular cells of the three germ layers, such as 
neurons and cardiomyocytes (16). 
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3D perfusion-based bioreactors have previously been demonstrated to allow the formation of 
tissues in a collagen-scaffold over prolonged times periods, as they guarantee the maintenance of 
cells in a controlled environment (17-22). The perfusion provides access of nutrients even 
towards cells residing in the centre of the scaffold. The bioreactors enable efficient cell growth 
while maintaining optimal surviving rates (23). Currently, the perfusion-based bioreactor has 
been used to produce several different tissue types in tissue engineering (17, 21, 22). A feeder-
based bioreactor has been established previously for the formation of teratoma-like tissue out of 
undifferentiated stem cells (24). Although structures of all three germ layers were generated 
successfully, this bioreactor system has not found widespread application due to the complexity 
of the device.  
For this reason, we focus on a user-friendly 3D perfusion-based bioreactor system (perfused 
culture) for the the establishment of an in vitro system, that allows the formation of teratoma-like 
tissue. The novel method should be animal-sparing and well standardized, simple to handle and 
allow to obtain results faster than with the conventional in vivo assay. The differentiation 
behavior of hPSC cultured in the perfused system was examined by the analysis of differentiation 
parameters in the culture medium, at RNA level and by histology. These results were compared 
with the EB culture and the in vivo teratoma assay in immunodeficient mice. 
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3. Material and Methods 
3.1 Cultivation of human embryonic stem cells (hESCs) 
3.1.1 hESC lines 
The hESC line CHES-6 was derived from the inner cell mass (ICM) of a hatched blastocyst and 
its pluripotency has been characterized as already published in our previous study (25). The 
abnormal hESC line (CHES1) was provided by Prof. A. Feki, Geneva, Switzerland (26).  
 3.1.2 Cultivation and irradiation of human foreskin fibroblasts 
Human foreskin fibroblasts (American Type Culture Collection (ATCC CRL2429)) were 
expanded on Petri dishes under standard conditions using IMDM (Gibco, catalog no. 12440053), 
10% FBS (GIBCO, catalog no.16000-044) and 50 U/ml Penicilin, 50 mg/ml Streptomycin 
(Invitrogen, catalog no. 15140-122). The fibroblast cultures were mitotically inactivated using 
gamma-irradiation (35 Gy). The irradiated fibroblasts were plated in a concentration of 0.1 x106 
cells/ml and kept in culture for 5 days before they were used as feeders for sustaining the growth 
of hESC. The feeder cell culture medium corresponds to the fibroblast medium. 
3.1.3 Maintenance culture of hPSCs cells  
hPSCs (CHES6, CHES1 and iPS) were grown on a feeder layer of irradiated human foreskin 
fibroblasts in culture medium consisting Knockout DMEM (Invitrogen, catalog no.10829-018), 
20% of Knockout Serum Replacement (Gibco, catalog no.10828028), 2 mM L-Glutamax 
(Invitrogen, catalog no. 35050-038), 1% of nonessential amino acids (Invitrogen, catalog no. 
11140-035), 0.05 mM mercaptoethanol (Invitrogen, catalog no. 11140-035), 50 U/ml Penicilin, 
50 mg/ml Streptomycin (Invitrogen, catalog no. 15140-122) and 8 ng/ml human recombinant 
basic fibroblast growth factor (βFGF; R&D Systems, catalog no. 234-FSE-025/CF). The hPSCs 
were cultured under standard conditions (37 °C and 5% CO2 in humidified air) and the media 
were changed on a daily basis. The hESC colonies were passaged by mechanically scraping off 
the feeder layer into 4-16 pieces, depending on the size of the colony. They were transferred with 
a pipette to new feeder layer, which was washed twice with PBS and subsequently hPSC medium 
supplemented with βFGF was added. The cells were passaged once per week. 
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3.2 3D culture conditions 
3.2.1 Embryoid body formation and cultivation 
hESC cells were scratched from the feeder layer after treatment with Accutase (Gibco, catalog 
no. A1110501) for 15 minutes at 37 ºC. The generated dissociated cells were further cultured in 
suspension at a concentration of 0.3 x106cells/ml for 24 hours in hPSC culture medium without 
the growth factor βFGF but supplemented with 10 µM ROCK inhibitor (RI) (Sigma, catalog no. 
Y0503) in non-tissue culture-treated dishes (Costar 24 well plate, Corning, catalog nr. 3473).  
After 24 hours, the generated aggregates were then further cultivated in suspension using 
standard hESC medium without any supplements (no ßFGF, no RI) for up to 8 weeks.  
3.2.2 Culture conditions for static and perfused culture systems 
For the 3D non-perfused (static) culture conditions, 12-well-plates were coated with 2% agarose 
to avoid adherence. The EBs were re-suspended in 10µl and seeded on a collagen type I scaffold 
sponge (Ultrafoam®, Avitene) with a diameter of 4mm.  After letting the cells adhere to the 
scaffold for 30 minutes at 37 °C, 2ml of basic hPSC medium without any growth factor or 
inhibitor (see maintenance culture of hPSCs) was added to the well and were subsequently 
cultured for 8 weeks. Media change was performed every other day and collected and stored at -
80°C for further analysis. 
For the 3D perfused system, a commercially available bioreactor was used (Cellec Biotek AG). 
Collagen type I scaffold sponge (Ultrafoam®, Avitene) with a diameter of 8mm were hydrated in 
culture medium and then placed in the bioreactor between two silicon rings plus an additional 
reducer ring to a final available area for direct perfusion with a diameter of 4mm. Once in the 
bioreactor, the aggregates, generated out of 0.3 x106 dissociated cells, were seeded on a collagen 
sponge positioned in the bioreactor. Subsequently 10ml of basic hPSC medium without any 
supplement was added. The perfusion flow rate was set at 0.1 ml/min to guarantee a superficial 
velocity of 100µm/sec. Media change was performed every other day and collected and stored at 
-80°C for further analysis. 
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3.3 Generation of hPSCs-derived teratoma 
The in vivo teratoma formation of the different hPSC lines was generated in immune-incompetent 
non-obese diabetic/severe combined immune-deficient (NOD/SCID) mice (Charles River 
Laboratories). All animal experiments were performed in accordance with the Swiss Animal 
Protection Law with the approval of the Basler Cantonal Veterinary Department. Around 50 
colonies with about 200 of undifferentiated hESCs were mixed with matrigel (BD, catalog no. 
356237) and injected subcutaneously into the flank of an 8-to 10- week-old NOD/SCID mouse. 
The resulting tumors were excised 3 and 8 weeks later. 
3.4 Measurement of AFP in the culture medium 
The releasing protein AFP (alpha-fetoprotein) was measured every other day in the circulating 
medium of the bioreactor and in the supernatant of the static conditions. The presence of AFP (10 
µl) was determined with an electrochemiluminescence assay (ECLA) according to standard 
procedures. These measurements were performed on the automatic Coba 800 system (Roche 
Diagnostics) in the central laboratory facilities of the University Hospital of Basel. 
3.5 DNA measurement 
We examined the cell growth and survival in the static and perfused culture by measuring the 
quantity of DNA. Briefly, samples of both culture conditions were incubated with 0.15% of 
collagenase IV at 37 °C (Gibco, catalog no. 17104-019) until the collagen scaffold was 
completely digested (30-60 min). The amount of DNA was measured with the CyQuant Cell 
Proliferation Assay (Invitrogen, catalog no. C7026) according to manufacturer’s instructions. The 
fluorescence was measured with Synergy H1 Hyprid multi-mode microplate reader (BioTek 
Instruments). The amount of DNA was calculated using a regression curve.  
3.6 Real-time quantitative PCR 
Total cellular RNA was extracted by using NucleoSpin RNA II kit (Macherey–Nagel, catalog no. 
740955) as described in the manufacturer`s instructions. 300 ng of total RNA was used for first 
strand cDNA synthesis by SusperScript II Reverse Transcriptase (Invitrogen, catalog no. 
18064.014) with 0.5 µM of deoxynucleotide triphosphates (dNTPs; Invitrogen, catalog no. 
10297-0189) and 5 ng/ µL random hexamer primers (Invitrogen, catalog no. 48190-011). The 
cDNA of each sample was used to detect expression of genes listed in table 1. The primers were 
 61 
synthesized by Microsynth (Balgach, Switzerland). One-tenth of each cDNA was used per qPCR 
reaction by using Power SYBR-Green PCR Master Mix (Applied Biosystems, catalog no. 
4367659. The qPCR reaction was done in an ABI 7500 Fast Real- Time PCR System (Applied 
Biosystems). The gene expression was normalized using GAPDH as reference gene.  
 
 
 
Table 1: Primer sequences for qPCR 
Primer Sequences 
AFP F: 5'-GGC AGC CAC AGC AGC CAC TT-3' 
R: 5'-GCA CTG GCC AAC ACC AGG GT-3' 
Brachyury F: 5'-AAG GCC CAG GTC CCG AAA GAT G-3' 
R: 5'-CCG TGT GCT CCT CCA CTG CTT TG-3' 
CDX2 F: 5'-CAG AGC CCT TGA GTC CGG TG-3' R: 5'-GGC TCA GCC TGG AAT TGC TCT G-3' 
GAPDH F: 5'-AGC CAC ATC GCT CAG ACA CC-3' 
R: 5'-GTA CTC AGC GGC CAG CAT CG-3' 
GFAP F:  5'-TCA TCG CTC AGG AGG TCC TT-3' 
R:  5'-CTG TTG CCA GAG ATG GAG GTT-3' 
HAND1 F: 5'-GCC GTG AGA GCA AGC GGA AAA-3' 
R: 5'-GGG CCT CGG CTC ACT GGT TT-3' 
Nanog F:  5'-TGG TGT GAC GCA GAA GGC CTC AGC A-3' 
R:  5'-CCC AGT CGG GTT CAC CAG GCA TCC C-3' 
OCT4 F:  5'-ATG GCG TAC TGT GGG CCC CAG GTT-3' 
R:  5'-TCC GGG GAG GCC CCA TCG GAT TGT-3' 
PAX6 F: 5'-CGT GGA ATC CCG CGG CCC CC-3' 
R: 5'- GAG TCC GGC AGT GGC CGC CC-3' 
α-SMA  
F: 5'-AAG GCC GGA GCT AGG AGT CCA-3' 
R: 5'-GAG GCA AAG GGC TGG TCC CTG-3' 
SOX17 F: 5'-GGC GCA GCA GAA TCC AGA-3' 
R: 5'-CCA CGA CTT GCC CAG CAT-3' 
βtub3 F: 5'-GAG ATC CTG CAC ATC CAG GCC GG-3' 
R: 5'-TCC GCT CCA GCT GCA AGT CCG-3' 
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3.7 Immunohistochemistry (IHC)  
Tissue samples were retrieved after 3 or 8 weeks of culture in each of the various conditions and 
fixed in 4% paraformaldehyde, then embedded in paraffin (TPC15 Medite) and subsequently cut 
serially in 5 µm sections. Hematoxylin and eosin (H&E) staining were carried out following the 
standard protocol. IHC was performed using the standard streptavidin-biotin-peroxidase 
procedure. Tissue sections obtained from the different study groups were treated with 10% 
normal goat serum for 30 min and incubated with the primary antibodies listed in table 2 
overnight at 4 °C. Blockage of endogenous peroxide activity was performed after 30 min of 
incubation with 3% H2O2 (Sigma, cat.no. H1009). The antigen-antibody reaction was visualized 
using the avidin-biotin peroxidase complex (Vectastain ABC kit, Vector Laboratories, PK-6101) 
and diaminobenzidine (DAB) as the chromogen (Impact DAB EqV, Vector Laboratories, SK-
4103). Sections were counterstained with hematoxylin. For every antibody-negative control was 
performed by omitting the primary antibody. The histological and IHC sections were analysed 
with an Olympus BX63 Apollo microscope. 
Table 2: Antibodies for IHC 
Antibodies Dilution Supplier 
Anti- AFP 1:200 Cell Marque (EP209) 
Anti- Brachyury 1:100 Abcam (ab20680) 
Anti- Calretinin RTU* Leica Biosystems Bond (PA0346) 
Anti- CDX2 RTU Abcam (ab765419) 
Anti- CD31 RTU Leica Biosystems Bond (PA0250) 
Anti- Desmin RTU Leica Biosystems Bond (PA 0032) 
Anti- Ki67 RTU 
 Biosystems (275R-18) 
Anti- LU5 1:1000 BMA Biomedicals (T-1302) 
Anti- Pax6 1:100 BioLegend (Poly19013) 
Anti- p63 RTU Leica Biosystems Bond (PA0103) 
Anti- α-SMA RTU Leica Biosystems Bond (PA0943) 
Anti- Synaptophysin RTU Leica Biosystems Bond (PA0299) 
Anti- βtub3 1:2000 Abcam (ab18207) 
* RTU= Ready to use  
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3.8. Coloration of sections 
Alcian-blue and periodic acid Schiff (AB-PAS) staining were used to stain structures containing 
glycogens, often found in mucus. The combination of the AB- and the PAS-techniques are 
commonly used to differentiate between neutral and acetic mucosubstances (2450077). The 
stainings were performed according to the manufacturer’s instructions using 1% Alcian blue 
(Sigma, cataog no. A5268), 0.3 % periodic acid and the Schiffs reagent (Morphisto, catalog no. 
11686). Masson fontana staining was used for the visualisation of argentaffin cells and melanin 
in the tissues. The staining was performed according to standard protocol using ammonical silver 
solution (25% of ammoniac and 10% of silver nitrate) and 0.1% of nuclear fast red solution 
(Merck, catalog no. 1.00121.0500). Melanin reduces the ammoniacal silver nitrate to metallic 
silver and this leads to the black appearance. 
3.9 Immunofluorescence 
The viability staining was performed with the live/dead fixable dead cell stain kit (Molecular 
probes L23101). The scaffold-based generated tissues were retrieved from the bioreactor and 
from the static culture followed, were firstly washed with PBS. The staining of the tissue was 
performed in 1 ml PBS by adding 2 µM calcein (stains living cells in green) and 4 µM ethidium 
homodimer (stains dead cells are stained red) for 30 min at room temperature and protected from 
light. Subsequently, the tissues were washed with PBS and analysed in a chamber slide. 3D 
images were acquired by Nikon confocal A1 microscopy with a Plan Apo 10x NA 0.75 objective 
using 0.25 µm z-stack step size. Three images per construct have been performed. The images 
were constructed and analysed with the Software Imaris X 64 7.6.5.  
3.10 Grading system  
Every sample of the three experimental groups (EBs, perfused culture and in vivo) was serially 
sectioned and stained for each of the selected markers (CDX2, α-SMA and βtub3). Subsequently, 
every section of each condition was analysed and for each marker expression the highest visible 
grade was given. The grading system distinguishes four grades of structural integrity: 
• Grade 0: negatively stained sections for these particular markers. 
• Grade 1 : poorly differentiated structures (disorganized). 
• Grade 2 : moderately differentiated structure showing some degree of organization. 
• Grade 3 : well differentiated and recognizable structures. 
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3.11 Statistical analysis 
All experiments were performed at least three times independently. Graphs and statistical 
analysis (unpaired one-way and two-way ANOVA) were implemented in Prism. P-values of < 
0.05 was considered statistically significant and are highlighted with *, p-values of <0.01 are 
highlighted with **, p-values of <0.001 are highlighted with ***. Error bars represent the 
standard error of the mean (SEM). 
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4. Results 
4.1 Set up of a 3D perfusion-based bioreactor system to culture differentiating hESCs 
(CHES6). 
In a first phase, two seeding procedures were tested to ensure the optimal seeding and culture 
condition of CHES6 in the perfused system. Dissociated CHES6 were either cultured statically in 
suspension in presence of rock inhibitor (RI) for 24 hours or injected directly into the bioreactor 
system supplemented with RI (Figure 1A). Both procedures were expected to allow aggregation 
of the cells. In the first method, small aggregates of CHES6 were further seeded manually on the 
scaffold of the perfused system and subsequently cultured in the presence of standard hPSC 
medium in the absence of any growth factor and RI. In the second method, CHES6 were injected 
directly into the perfused system, in which aggregates are formed under constant perfusion with 
medium containing the RI allowing the cells to integrate onto the scaffold. In both methods, 
medium was changed after 24 hours to the standard hPSC medium without the RI or growth 
factors.  
 
Figure 1: Assessment of different seeding procedure in the perfused culture. (A) Experimental scheme for the 
two seeding methods for culturing a teratoma-like tissue. (B) H&E staining of representative sections from the 
dissociated cell culture (lower panel) and the aggregates culture (upper panel) after 3 weeks of perfused culture 
(scale bar, 100 µm). 
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Cells were then cultured in differentiation-permissive medium for 3 weeks followed by 
histological analysis of the tissues samples obtained (Figure 1B). The first method using pre-
formed aggregates in suspension gave rise to various distinct structures. In contrast to the second 
method where the cells are aggregated within the scaffold, cells were mostly spread over the 
whole scaffold and formed only few small structures (Figure 1B). Therefore, we concluded that a 
first aggregation of cells in static suspension was needed to secure efficient structure formation in 
the perfused culture. 
Since we load our system with aggregates formed in suspension, the exact number of cells used 
to load the perfused system could not be evaluated. We tested if the concentration of dissociated 
cells placed in suspension build always the same amount of aggregates. Therefore, we measured 
the number of cells to be seeded on the scaffold as the number of dissociated cells taken from the 
feeder-based CHES6 culture and placed in suspension. We started culturing 0.3 x106 of 
dissociated cells in suspension and measured the amount of DNA of the aggregates formed after 
24 h of culture in suspension (Figure 2A). The aggregates formed out of 0.3 x106 of dissociated 
cells cultured in suspension contained 160 ng/ml of DNA (Figure 2B). Hence, the concentration 
needed to form a teratoma-like tissue in the perfused culture is 0.3 x106 of dissociated cells. 
 
Figure 2: Standardization of the seeding procedure in the 3D-perfused culture. (A) Experimental scheme for 
the measurement of the amount of DNA of the generated aggregates out of 0.3 x 106 dissociated stem cells. (B) 
Amount of DNA measured in the generated aggregates of CHES6 after 24 hours of static suspension culture 
(n=5). 
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We then examined whether the 3D-scaffold system indeed required perfusion with circulating 
culture medium to achieve better results. To that purpose several determinants of cell growth and 
differentiation were compared between the perfusion-based culture and a non-perfused scaffold 
condition (static culture) (Supplementary Figure S1). Briefly, aggregates derived from CHES6 
were embedded into a collagen scaffold and cultured dynamically under perfusion or statically in 
a 12-well plate during the same time interval. We first compared the viability of the hPSCs in 
static and perfused cultures, using calcein AM and ethidium homodimer-1 dyes, staining living 
cells and dead cells respectively (Figure 3A). After dissociation and seeding, and before the cells 
adapted to the new culture conditions, we initially observed a significant amount of cell death. 
After one week of culture around 80% of cells survived in both conditions, whereby in the static 
culture the SEM was higher within the triplicates (83% ± 2 SEM in perfused culture and 75% ± 
10.3 SEM in static culture). Moreover, we observed that the inner part of the scaffold was mainly 
composed of dead cells with a rim of living cells. 
Between 1 and 3 weeks of culture, the number of living cells increased under perfusion. As a 
consequence of culture stabilization, the percentage of living cells increased, reaching almost 
100% in the perfused system (96% ± 0.9 SEM). Instead, in the static culture the cell survival was 
lower (77% ± 5.0 SEM). After 8 weeks of culture, the proliferation of cells stopped, as the 
differentiation process was initiating and more advanced structures progressively formed. In both 
culture conditions cell viability decreased. This likely reflected the lack of various survival 
factors required in vitro by the numerous types of differentiated cells produced in such a 
heterogeneous differentiation system, with cells loss not being anymore balanced by the 
generation of new cells.  
These results were confirmed by measuring the DNA content for each culture condition over time 
(Figure 3B). After 1 week of culture, the amount of DNA was lower in the static culture. In the 
presence of equivalent cell viability in both culture conditions (Figure 3A), the lower amount of 
DNA in the static cultures indicates a lower rate of cell recovery and proliferation. Compared to 1 
week of culture, after 3 weeks the amount of DNA increased 4x with the static culture and more 
than 6x with the perfused culture (Figure 3B). After 8 weeks a decrease of the DNA content was 
observed in both conditions, which was significantly lower under perfusion (Figure 3B). 
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Figure 3: Cell and tissue characteristics of the perfused and static cultures. (A) Cell viability staining (green= 
living cells, red= dead cells). Fluorescent microscopic images of representative samples of tissue grown after 
static or perfused culture, after 1, 3 and 8 weeks. Quantitative analysis of the percentage of living cells (green) 
cultured in both conditions (n=3). (B) Measurement of the amount of DNA of cells grown in either static or 
perfused cultures over time (n=3). (C) AFP-release into the surrounding culture medium measured over time 
during two different culture conditions (n=6). (D) H&E-stained representative sections of samples retrieved 
after 3 and 8 weeks of static or perfused cultures (scale bar, 100 µm). Error bars indicate ±SEM. *P < 0.05, 
***P < 0.01. 
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We then analysed the effect of perfusion on the ability of the cells to differentiate and to become 
organized into specialized structures. We determined the initiation of differentiation by 
measuring the release of  AFP, an early marker of endoderm,  into the culture medium (27) 
(Figure 3C). After 1 week of culture almost no AFP-release was detected, while after 3 weeks the 
AFP-levels strongly increased in both conditions giving an evidence of cell commitment. The 
release was significantly higher, almost 3-fold, in the perfused culture system as compared to the 
static culture. This difference suggests that the lower cell growth observed in static culture 
condition (Figure 3B) was not due to a premature entry into the differentiation process. After 8 
weeks of culture AFP-release decreased in both conditions, illustrating the transient expression of 
AFP during differentiation. These results demonstrate that the commitment of differentiation to 
the endoderm was more efficient in the perfusion system than in the static counterpart.  
We then examined the formation of differentiated structure with Haematoxylin & Eosin staining 
(H&E) after 3 and 8 weeks of culture in both conditions. After 3 weeks, we observed that cells 
cultured under static conditions were spread over the whole scaffold, but were almost unable to 
form recognizable organized structures. In contrast, under the perfused culture conditions cells 
were able to produce organized structures (Figure 3D). After 8 weeks of culture, cystic structures 
were identified in both culture conditions, but better organized structures were formed under 
perfused culture.  
Collectively, the perfusion-based culture system provides an environment which promotes higher 
cell viability, better differentiation, and supports the generation of tissue-like structures. 
Therefore, we decided to further validate the perfused system as a valuable culture tool for the 
formation of teratoma-like tissue in vitro. 
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4.2 Spontaneous differentiation of CHES6 into the three germ layers during perfused 
culture 
We examined the time course of the differentiation process during perfusion of the 3D-scaffold 
by determining the expression levels of early and late markers of the three germ layers. We 
compared these results with those of the conventional in vitro EB culture model described above, 
often used as an initial method for initiating spontaneous differentiation towards the three germ 
layers (28). In both culture conditions, after one week of culture, Oct4 and Nanog, common 
stemness markers for self-renewal, were not expressed anymore (Figure 4).  
 
Figure 4: Pluripotency status of hPSCs cultured in two different conditions (A-B) Assessment of the 
expression level of two pluripotency markers, Oct4 and Nanog, after 1 week of perfused and EB culture in 
comparison to the initial undifferentiated population. Error bars indicate ±SEM. **P < 0.01. 
Concomitantly, we investigate the degree of commitment assessing the expression level of the 
specific germ layer markers AFP, brachyury, and PAX6 respectively for endoderm, mesoderm, 
and neuroectoderm. In both culture conditions, after 1 week, the degree of commitment increased 
with the expression of all three markers three-  to five-fold more than in the initial cell population 
(Figure 5).  
In the perfused culture, the expression of AFP and PAX6 expression continued to increase during 
the two following weeks (two-fold and three-fold, respectively), while the expression levels of 
brachyury remained stable (Figure 5A). As expected, as these genes are expressed only 
transiently during the specification of the three germ layers, their expression dropped after 8 
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weeks of culture suggesting that the process of differentiation was ongoing and that the 
committed cells were progressing into more specialized cells (29, 30). 
In the EB culture, the situation was much more erratic. While the three genes became expressed 
after 1 week of culture, only AFP continued to be expressed over the entire observation period, 
corresponding to normal and undisturbed development. The expression of brachyury prematurely 
decreased after 3 weeks, while the expression of PAX6 persisted longer than expected (Figure 
5A), indicating that the EB culture system is less favourable to the differentiation process than 
the perfused culture. By IHC, we confirmed the presence of cells for all three markers in both 
culture conditions (Figure 5B), but the defined structures were found only in the perfused culture 
system (right panel).  
 
 
Figure 5: Assessment of the commitment potential of hPSCs under perfused culture. (A) Comparative RT-
qPCR analysis of the early markers AFP, brachyury and PAX6, representing each of the three germ layers after 
8 weeks (n=3). (B) IHC of AFP, brachyury and PAX6 in the generated teratoma-like tissue (right panel) and in 
the EBs (left panel) after 3 weeks of culture (scale bar, 100 µm). Error bars indicate ±SEM. *P < 0.05, **P < 
0.01. 
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To examine whether committed cells were able to differentiate further into more specialized 
tissue types during prolonged culture, the expression of more advanced differentiation markers 
was compared between the two in vitro cultures by RT-qPCR (Figure 6). For the endoderm, we 
focused on SRY-box 17 (SOX17), which is implicated in endoderm determination and 
maintenance (31) and CDX2, which is a major regulator of genes expressed in the intestinal 
epithelium (32) (Figure 6A). For the mesoderm, the transcription factor heart and neural crest 
derivatives 1 (HAND1), which is required for the differentiation into heart tissue (33) and alpha 
smooth muscle-actin (α-SMA) which is a key mediator of the differentiation of heart and muscle 
tissue (34) were studied (Figure 6B). Regarding the neural lineage, ß-III-tubulin (ßtub3), a 
marker for young neurons (35) and glial fibrillary acidic protein (GFAP), a marker for astrocytes 
(36), were examined (Figure 6C). Expression of all these markers was detected after 3 weeks in 
both culture conditions, confirming that the two systems allowed further differentiation after cell 
commitment. 
In the perfused culture, the evolution of expression level of those differentiation markers between 
3 and 8 weeks was coherent with their order of appearance during normal in vivo development. In 
endodermal lineage, SOX17, which marks also early endodermal cells, was highly expressed 
after 3 weeks, while the expression of CDX2, which labels differentiated intestinal cells, rose 
only after 3 to 8 weeks (Figure 6A). In the mesodermal lineage, expression of markers of 
different types of muscle cells were already detectable at 3 weeks, but their level increased as 
differentiation proceed (Figure 6B). Finally, in neural lineage, the neuronal marker ßtub3 was 
already highly expressed after 3 weeks, while the astrocytic marker GFAP was poorly detectable 
at that time, but became predominant after 8 weeks (Figure 6C). That ranking is reminiscent of 
the sequential generation of neural subtypes during embryonic development; first neurons, then 
glial cells.  
In the EB culture, expression of all markers was detected at levels similar to that observed in the 
perfused culture, indicating that differentiation was globally similarly efficient in the two 
systems. However, the time-course of differentiation seems to follow much more poorly what 
happens during in vivo development. On one hand, SOX17 in endoderm or α-SMA in mesoderm 
behaved similarly to what was observed in the perfused culture. On the other hand, CDX2 in 
endoderm, HAND1 in mesoderm and GFAP in neurectoderm showed faster upregulation. For 
CDX2 and HAND1, expression level was unexpectedly even higher at 3 weeks than after 8 
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weeks of differentiation. In neurectoderm, the disturbance in differentiation time-course led 
apparently to simultaneous rather than sequential generation of neuronal and glial cells. Thus, the 
perfused culture seems to better reflect the organization of tissues, which allows the interaction of 
cells required to reproduce normal developmental events.  
 
Figure 6: Comparative analysis of the late differentiation potential of hPSCs over time with RT-qPCR. (A) The 
endodermal markers SOX17 and CDX2 were examined in the perfused culture and the EB culture after 3 and 8 
weeks in culture. (B) The expression of the mesodermal markers HAND1 and α-SMA were tested in both 
conditions after 3 and 8 weeks in culture. (C) The expression of the neuroectodermal marker ßtub3 and of the 
astrocytic marker GFAP were determined in the perfused culture and in the cultured EBs after 3 and 8 weeks. 
Error bars indicate ±SEM. *P < 0.05.  
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4.3 Structure formation along the three germ layers 
Since we are particularly interested in the feasibility of cells cultured into 3D-perfused system to 
build various structures derived from the three germ layers, we assessed different specific 
markers linked to particular structures in the generated teratoma-like tissue. Indeed, a broad 
spectrum of different markers was expressed at 3 and/or 8 weeks of perfused culture (Figure 7) 
 
Figure 7: Histological overview of teratoma-like tissue generated in the perfused culture. (A) Pancytokeratin 
(Lu5) staining decorating epithelial cells. (B) Desmin positivity in myogenic cells. (C) Positive AB-PAS 
staining showing glands. (D) Synaptophysin expressed by neural and neuroendocrine cells. (E) Singh-staining 
showing melanin containing cells. (F) P63 expression displaying squamoid and basaloid cells (G) Calretinin 
immunostaining exhibiting mesothelial cells. (H) CD31 positivity in endothelial cells of capillary vessels. 
(scale bar= 100 µm). 
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Epithelial cells were identified by a positive staining of pancytokeratin (LU5), while a negative 
staining of this marker was used to detect nervous tissue (like neuronal tubes) (7A). Staining for 
desmin was used to identify differentiation to muscular cells (7B). With Alcian-Blue and the 
Periodic Acid-Schiff reaction (AB-PAS) glands with or without goblet cells were detected (7C). 
Cells of neural structures and neuroendocrine tissue were identified by a staining for 
synaptophysin (7D). By melanin staining (Singh) cells of the retinal epithelium were identified 
(7E). Cells with squamoid and/or basaloid differentiation were highlighted with the marker p63 
(7F). Mesothelium was confirmed by the expression of calretinin (7G) and CD31 expression 
displayed endothelial cells of capillary vessels (7H). 
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4.4 Reliability of the system 
As all experiments described above were carried out with the hESC line CHES6, the performance 
of the perfusion-based bioreactor was examined with two other stem cell lines. One stem cell line 
was a hiPSC line (iPS) newly generated in our laboratory, while the other is a teratocarcinoma-
like hESC line (CHES1). This latter cell line has an abnormal karyotype (61 XX and presence of 
iso-chromosomes) and is unable to differentiate into normal teratoma tissue. When grafted in 
vivo, it forms malignant tumors still containing many undifferentiated cells (26, 37). After three 
weeks of culture in the perfused culture, different parameters were compared in the generated 
tissue of the three cell lines CHES6, iPS and CHES1 (Figure 8). As previously demonstrated with 
the reference CHES6 line, after 3 weeks of culture proliferation of cells still continued, but the 
differentiation process was already progressing. Therefore, we selected that time point to 
compare the performance of the three cell lines in the perfused culture. 
Staining with the proliferation marker Ki67 (Figure 8A) and visualisation of structure formation 
by histology after H&E staining (Figure 8B) demonstrated that the iPS switch from proliferation 
to differentiation followed a time course very similar to CHES6. In the teratoma-like tissue 
formed with iPS, the ratio of still proliferating cells was roughly equivalent to what was observed 
with CHES6 (Figure 8A) and various structures of different origins could be recognized (Figure 
8B). The pluripotent stem cell characteristics of iPSC line were confirmed by its ability to form 
teratoma in vivo after transplantation into immunodeficient mice (Supplementary Figure S2). 
With CHES1, in contrast, a strikingly high number of proliferating cells was detected (Figure 8A) 
and no distinct structure of any of the three germ layers was recognized (Figure 8B). 
We have previously shown that AFP release can be used as a non-destructive indirect indicator to 
assess stem cell commitment to the endoderm and that the highest release of AFP into the 
circulating culture medium can be detected after 3 weeks of culture. We therefore examined 
AFP-release into the culture media of the three cell lines. As with CHES6, high levels of AFP 
were measured in the circulating culture medium during the differentiation of the iPSC line 
(around half the level found in CHES6) (Figure 8C). In contrast, no AFP-release could be 
detected in the circulating medium during the differentiation of CHES1 (Figure 8C). Absence of 
commitment after three weeks of culture of CHES1 was confirmed at the RNA level, as no 
significant expression of AFP, nor of brachyury and PAX6 was measured (data not shown). 
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Figure 8: Assessment of the performance of the perfused system with 3 different hPSC lines after 3 weeks in 
culture. (A) Comparative analysis of the proliferation of three different hPSC lines by a Ki67 staining. (B) 
H&E-stained representative sections of samples generated by 3 different hPSC lines after 3 weeks of culture 
(C) AFP-release in the perfused culture using 3 different hPSC lines (n=4) (scale bar, 100 µm). Error bars 
indicate ±SEM. 
 
In conclusion, these results clearly demonstrate that the 3D perfused bioreactor allows the 
distinction of the pluripotency between a normal hPSC line from that of an abnormal hPSC line 
by the attempt of generating a teratoma-like tissue after three weeks of culture. 
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4.5 Grading of structures from the three germ layers  
We performed a semi-quantitative analysis to evaluate the differentiation quality of the structures 
formed either in vivo after transplantation into immunodeficient mice or in vitro in the perfused 
culture or from cultured EBs. We established a grading system based on the differentiation 
degree of particular structures derived from the three germ layers. It was adapted from a tumor 
grading system, previously defined by the WHO (38). The structure of intestinal epithelium, 
muscle fibers and early neural tubes are commonly used structures to identify teratoma in vivo, 
mostly after staining with H&E (9). We selected one marker per germ layer to properly identify 
each of these structures representing the three germ layers: CDX2 for endoderm as expressed in 
intestinal epithelium, α-SMA for mesoderm expressed in muscular fibres and ßtub3 as expressed 
in young neurons originate in neural tubes representing neuroectoderm. The grading system 
distinguishes four grades of structural integrity (Figure 9). The detailed procedure of scoring the 
stained sections is explained in Material and Methods. 
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Figure 9: Scoring system with different grading categories. (A-C) Negatively stained sections for CDX2, α-
SMA and ßtub3. (D-F) Single cells are stained with the particular marker. (G) Abortive intestinal epithelium. 
(H) Subepithelial linear cell groups (I). Abortive neural tube formation (J) Intestinal epithelium (K) Muscle 
fibers (L) Neural tube formation + organized cell groups (scale bar, 100 µm). 
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After 3 weeks of culture (earliest possible time point with highest expression of commitment in 
vitro) and after 8 weeks (time needed to build a teratoma in vivo) we compared the scoring results 
achieved with the three different culture conditions. By comparing the two in vitro cultures both 
after 3 and 8 weeks for all markers the grade level of the structures produced in the perfused 
system was significantly higher than the level reached with the EB culture (Figure 10A). The 
grade level of the structures built in the perfused system could reach the same level as the in vivo 
conditions even after 3 weeks of culture. In contrary, the grade level achieved with the in vitro 
growth of EBs never reached the same grade level as with the in vivo system at both time points. 
In addition, the quality of the structures built in each EB was very diverse. Some EBs 
differentiated into organized structures whereas others acquired a cystic appearance. In most 
differentiated structures the cells expressed the required markers, but the observed structures 
usually remained disorganised and did not form a recognizable appearance.  
 
Figure 10: Comparison of the differentiation degree of particular structures among the three different culture 
conditions. (A) Comparative analysis of the grade-level of the markers CDX2, α-SMA and ßtub3 in the two in 
vitro systems and the in vivo system. (B) Comparative analysis of teratoma formation efficacy between the in 
vivo system and the perfused culture. Error bars indicate ±SEM. *P < 0.05, ***P < 0.001. 
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Finally, we compared the degree of efficacy rate of the conventional in vivo teratoma assay with 
the perfused system (Figure 10B). Out of 9 in vivo experiments, a real teratoma was detected in 
only 3 cases, while one mainly consisted of a big liquid cyst. In contrast, the perfusion-based 
culture produced teratoma-like tissues in 90 % of all experiments (9 out of 10 cases). The 
perfused culture system is more reproducible than the conventional in vivo assay. 
In summary, the grading of the EB in vitro culture is clearly inferior to that reached with the 
perfused system. The grading of the tissue quality achieved with the perfused bioreactor system is 
similar to the grading of the tissue quality in vivo, but was in our hands much more reproducible. 
In addition, teratoma-like tissue can already be obtained after three weeks of perfused culture, 
whereas in vivo growth to mature teratoma tissue mostly required 8 weeks after transplantation.  
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5. Discussion 
In this study we present a well-controlled and reproducible culture system for the demonstration 
of pluripotency of newly derived hPSC lines. Our experiments clearly illustarted that hESCs 
(CHES6) and iPSCs are able to produce teratoma-like tissue in the 3D perfusion-based bioreactor 
system.  
We demonstrated that the perfused culture of both hESCs and hiPSCs supports cell growth and 
differentiation resulting in the rapid generation of viable tissues of the three germ layers. Our 
findings are in line with similar observations with other cell types cultured in this system in 
which was demonstrated that the dynamic culture environment of the perfused bioreactor ensures 
a continuous support of nutrients and oxygen, which leads to a maintenance of viable tissue and 
to the feasibility of the formation of larger tissue-like structures over prolonged time periods (19, 
21-23). 
The differentiation potential of hPSC in vitro is typically examined through the analysis of the 
expression of genes characteristic of the three germ layers after EB formation (28). Therefore, we 
investigated if our perfused system is able to let CHES6 commit and differentiate spontaneously 
into the three germ layers similar as with the EBs. In both the perfused culture system and in the 
culture of EBs Oct4 and Nanog, which are key transcription factors for the maintenance of 
pluripotency, are expressed in the undifferentiated starting population of CHES6 (39, 40). As 
soon as the cells start to differentiate, the expression of the pluripotency markers gradually 
disappears, whereas the expression level of differentiation genes starts to rise (41). The 
assessment at molecular level of commitment and late differentiation into to the three germ layers 
over time has clearly shown that the perfused system recapitulates better the in vivo 
developmental events than the EB culture. During early differentiation until 3 weeks, the cells 
highly express the commitment markers AFP, brachyury and PAX6. At 8 weeks, the expression 
levels of two markers (AFP and PAX6) already decrease, while the expression of brachyury is 
still stable. This is in accordance with the known transient expression of these markers during 
embryonic development (27, 42), while, in vivo, PAX6 is re-expressed later to regulate adult 
neurogenesis (43, 44). By investigating the expression of later markers of the three germ layers 
between 3 and 8 weeks of culture, we observed that after the commitment, the differentiation 
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process is ongoing and that upregulation of differentiation markers belonging to each germ layer 
roughly follows their order of appearance during embryonic development (45-47). 
However, after 8 weeks of culture, there was a remarkable variability in the expression of the 
various differentiation markers among samples. This can be attributed to the prolonged culture of 
CHES6 in the basic hPSC medium in the absence of any supplements supporting specific 
differentiation of certain tissue types. A defect in such specific requirements is also likely to be 
involved in the observed increase of cell death after 8 weeks in a culture system, which exhibits a 
remarkable capacity to sustain cell viability for several weeks. The markers of commitment and 
late differentiation are indeed expressed in the EBs but much more inconsistently.  
By the histological evaluation, which is the more stringent assessment of spontaneous 
differentiation (28), we could detect a clear difference in tissue differentiation between the two in 
vitro assays. The culture of EBs led to more heterogeneous results characterized by diverse 
qualities of structures. The expression of differentiation markers indicated that expected 
differentiated cells were indeed generated in the EB but they mostly failed to produce 
recognizable structures. With the newly established grading system, we could realize that the 
structure formation never reached the same grade level as the in vivo assay, regardless of the 
duration of the culture.  Others have published similar observations, demonstrating expression of 
markers of the three germ layers in the absence of any organized structures in 35-day-old EBs 
(48). Another study demonstrated the generation of a feeder-based perfusion system to generate 
teratoma-like tissue in vitro. Also there the culture of EBs resulted in a much lower degree of 
differentiation and tissue formation as the perfused culture (24). The variability of marker 
expression and structure formation among the EBs can be attributed to the stochastic nature of 
differentiation in such culture. Furthermore, it is known, that the differentiation potential of the 
EBs depends on their initial condition, given by their cell number and their size (13, 49). 
Depending on the size, the EBs may either develop organized structures or become cystic due to 
reduced mass transfer (15). The resulting heterogeneity of their terminal differentiation lead to a 
lower grading of the differentiated structures.  
In the perfused system, we could detect various structures derived from the three germ layers at 3 
and 8 weeks of culture. To define the differentiation capacity of hPSCs into a teratoma in vivo at 
least one structure per germ layer needs to be demonstrated. The identification of the tissue is 
 84 
usually done by H&E-staining of the sectioned tumor (9). The following structures, 
morphologically easy to detect, are usually reported as a proof of spontaneous differentiation in 
vivo: intestinal glands of the endoderm, cartilage of the mesoderm and neural tubes derived from 
the neuroectoderm (50-53). These structures were also detected in the in vivo grown teratoma 
produced by CHES6 and iPS. In the teratoma-like tissue generated in the perfused culture we 
detected intestinal glands and neural tubes, but not cartilage-like tissue. One explanation for the 
disability to the formation of cartilage-like structure is the basic culture medium, which is not 
supplemented with additional growth factors, such as TGFß, which is known to be an inducer of 
chondrogenic differentiation (54). Another possible reason could be that the system doesn’t have 
an appropriate niche for its generation as compared to the in vivo. In the in vivo assay matrigel is 
co-inoculated with hPSC as it is known to enhance the formation of teratoma in vivo (55). 
Matrigel is a gelatinous extracellular matrix (ECM) that contains various ECM proteins and 
growth factors such as ßFGF and TGFß (56). Thereby the cell survival and growth of the tumor 
are enhanced. Moreover, it promotes differentiation into various types of tissue (55, 57). The use 
of matrigel might have an influence in the chondrogenic differentiation in vivo due to these 
growth factors, but it is not clear to which extend and how exactly since the concrete composition 
of the matrigel is poorly understood (58). Furthermore, the mouse model itself may have another 
impact on the growth and differentiation pattern of the teratoma (59). Thus, instead of cartilage, 
we selected muscle fibers to represent the mesoderm. With the grading system, we could show 
that the perfused culture was able to mimic teratoma-like tissues from all three germ layers 
reaching similar grading levels as the teratoma tissues in vivo at 3 and 8 weeks of culture. These 
results demonstrate that the dynamic cell mass exchange in the bioreactor may mimic the cell 
mass exchange occurring in vivo. 
In comparison with the in vivo growth of teratoma in immunodeficient mice, the present 
bioreactor system produces teratoma-like tissue faster, as it was formed already after 3 weeks of 
culture with an efficiency of 90%. In contrast in only 33% of the cases a teratoma in vivo could 
have been built, which underlines the inconsistency of this assay (9, 60). Several approaches have 
been carried out to standardize the in vivo assay by defining distinct parameters. The best 
engraftment site, the minimum cell number and the best cell preparation have been defined by 
several laboratories to guarantee the best condition for teratoma formation in vivo (8, 55). Our 
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controlled and reproducible bioreactor system eliminates several of the possible variables existing 
in the in vivo assay.  
Another disadvantage of the in vivo assay is its duration, which can last up to 15 weeks (9). With 
the perfused bioreactor system, we could already detect at 3 weeks of culture if the newly derived 
hPSCs have a normal or abnormal behavior, even by a non-invasive way measuring the AFP-
release into the culture medium. This has been clearly demonstrated by culturing the 
teratocarcinoma-like line CHES1. Already after 3 weeks of culture, no structure formation was 
detected in the generated tissue. This was confirmed by the absence of AFP-release, into the 
surrounding culture medium. This result was in accordance to published knowledge concerning 
this abnormal hESC line (26, 37).  
An important aspect of the use of this new perfusion-based in vitro assay is the reduction of 
animal experimentation. The generation of a tumor in an immunodeficient mice may cause pain 
and harm (10). In consideration of the widespread use of hPSCs and with the technique of 
generating iPSCs, the number of animals to proof pluripotency by teratoma formation would 
thereby increase drastically . 
When compared to one other existing feeder-based bioreactor for the production of teratoma-like 
tissue, we could generate similar results revealing that the perfused culture is able to generate 
teratoma-like tissue similar to the in vivo culture (24). However, our bioreactor system is more 
user-friendly and it has been validated to an applicable tool using histological analyis. 
Based on these results we propose our novel bioreactor system to be used as a screening tool for 
the demonstartion of pluripotency, with which new hPSC lines can be tested within 3 weeks for 
their normal or abnormal differentiation behaviour. This model may be further used to compare 
different hPSC lines in their differentiation capacity using the established grading system. Since 
hiPSCs are promising in the field of regenerative medicine and disease modelling, the demand for 
the generation of newly derived hPSC lines is constantly increasing (61). Thus, this system can 
be further optimized for the use of disease modelling or for clinical application. Thereby the 
patien-derived iPS lines may be differentiated in a favoured tissue under perfused conditions. 
Moreover, it can become a valid system in the field of reprotoxicity, since the teratoma formation 
simulates the early embryonic development.(10). 
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6. Supplementary Data 
 
 
Supplementary Figure 1: Experimental scheme for the generation of a teratoma-like tissue under perfused and 
static conditions. 
 
 
Supplementary Figure 2: Histological overview of a generated teratoma in vivo with iPS after 8 weeks of 
incubation. (A) H&E-staining of the teratoma tissue (B) CDX2 expressed by cells of early intestinal tissue (C) 
α-SMA expression displays smooth-muscle like structures (D) Staining of btub3 showing young neurons (scale 
bar= 100 µm). 
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Summary and conclusion 
PSCs are powerful tools in basic research and promising for treating injuries, for disease 
modelling and drug discovery. Technological advances have made it progressively easy to 
generate iPSCs. Although the various generated lines are considered to be very similar in terms 
of stemness and their ability to differentiate, differences in their characteristics among lines also 
exist based on the origin, derivation and culture conditions. 
In chapter I we assessed the difference in gene expression and differentiation behaviour in 4 
generated hESC lines. We demonstrated that inherent differences were evident although the 
hESCs were derived and cultured in the same way. Spontaneous commitment during stem cell 
maintenance could be verified. However, the origin of variability among the hESC lines remains 
unclear. Several explanations exist, such as that the cells are genetically determined to be 
differently sensitive to external factors used to maintain stemness in vitro. It has been shown by 
various studies that the culture medium has a remarkable influence in the property of the cell to 
remain pluripotent or to start to pre-differentiate. Thus, it is important that the degree of stemness 
and the pre-differentiation potential of every newly created hESC line is well characterized. Our 
results clearly document the difficulty in the handling and characterization of newly created 
hPSC lines since the derivation- and culture- dependent variability together with the inherent 
differences clearly have an impact on the property of hPSC lines.  
A high variability not only exist in the derivation and maintenance of the hPSC lines but also in 
the techniques used for the characterization of these lines. The appropriate analysis and the 
preciseness of any particular test is determined by the investigator. This was also observed in the 
in vivo teratoma assay, which is the gold standard to demonstrate the pluripotency of stem cells. 
Despite its eminence, this test has never been standardized in terms of graft site, number of cells 
implanted and the cell preparation. These factors are all known to influence the development of 
teratoma in vivo. In addition, the way to analyze and report the result is considered as variable 
and inconsistent. This assay raises ethical concerns since hPSCs are inoculated into animals and 
when a tumor is formed, the animal suffers pain. Thus, in chapter II we demonstrated the 
establishment of a 3D perfusion-based culture system to generate a teratoma-like tissue, which is 
more standardized and reproducible as compared to the conventional in vitro and in vivo assay. 
 91 
The technique of 3D perfusion-based in vitro cultures has shown to be essential to ensure the 
generation of a teratoma-like tissue.  
Overall this work implies the complexity and the subsequent challenge of hPSCs in their proper 
definition and evaluation of pluripotency. HPSCs have the unique characteristic of their potential 
to differentiate into multi-lineages and their ability to self-renewal, which permits them to 
proliferate in their undifferentiated status. Consequently, these cells are promising for widespread 
application like understanding early development, cell therapy and disease modelling due to their 
unique capacity (1). However, the pluripotent state remains dynamic leading to genetic and 
epigenetic variation between the lines despite being functional pluripotent. It appears that the 
definition of the pluripotent state turns out to be more complex as expected and illustrates a 
weakness in the field of characterization of these cells. Some years ago, specific assays for the 
characterization of hPSCs have been established but they lack standardization (2). With the 
establishment of our in vitro system to build a teratoma-like tissue as described in chapter II, we 
could successfully go one step towards a standardized and applicable assay. However, to become 
a valid alternative or supplement of the existing assays for proving the differentiation capacity of 
the cells, additional validation steps will be required.  
In general, further work has to be addressed for the validation of pluripotency of novel hPSC 
lines. The so far existing assays are the main base for the evaluation of the pluripotency status but 
further refinements of these tests should be investigated. Moreover, for the purpose of using 
hPSCs for cell therapy and translation in clinical practice, quality and safety issues must be 
solved in order to generate hESCs and iPSCs (3). Depending on the future use of these cells, 
different levels of stringency in terms of pluripotency may be required. In case of the cell therapy 
application, it may not be essential that the line has the correct molecular pluripotency but rather 
the functional pluripotency being able to differentiate into cells that derive from all three germ 
layers (4). 
Additionally, the acquisition of genomic alterations during long-term culture must be prevented 
or, when they occur, detected. Therefore, it is essential that the pluripotency status of existing 
hPSC lines is assessed regularly especially before the cells will be further used. Culture 
conditions and derivation processes (especially for iPSCs) need to be constantly optimized to 
maintain the characteristics of hPSCs thereby avoiding genetic aberrations. The new existing 
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molecular tools (e.g. next generation sequencing) are promising in understanding the pluripotent 
state at a molecular level (5). The next generation sequencing is more often used but more work 
should be investigated in establishing a user-friendly application of the analysis of this data set. 
Together, further research efforts will have to address refined standards to assess the pluripotency 
status depending on the further applications of the cells. In this context, new technologies have to 
be officially involved in the evaluation process of hPSC lines. Ultimately, reaching this goal, a 
continuous and strong collaboration in the stem cell community is required to develop these 
novel standards. In this way, by an appropriate combination of the different assays, the use of 
hPSCs can hold its promise of bringing basic research and translation one step forward. 
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